Lung Cancer Considered: Recent Episodes
IASLC
Dr. Stephen Liu and Dr. Narjust Duma host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
Lung Cancer considered is funded in part by AstraZeneca, Bristol Myers Squibb, Lilly Oncology, and Merck KGaA.
Thymic epithelial tumors are rare but complex thoracic cancers that require specialized diagnosis and multidisciplinary management. In this episode of Lung Cancer Considered, Dr. Stephen Liu is joined by Dr. Nicolas Girard and Dr. Erica Pietroluongo to discuss the diagnosis, staging, and treatment of thymoma and thymic carcinoma, including current standards of care, evolving systemic therapies, and promising areas of research. They also highlight the importance of international collaboration in advancing care for patients with these rare malignancies.Guests:Nicolas Girard, MD, PhDHead of the Thorax Institute Curie Montsouris, Institut Curie, Paris, FranceErica Pietroluongo, MD, PhD Medical Oncologist, University Federico II, NaplesVisiting Scholar, University of Chicago
Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander Drilon, and Dr. Rosario Charo Garcia Campelo discuss the ARROS1 trial results, the drug's efficacy and safety profile, CNS activity, and where zidesamtinib may fit into current and future treatment strategies for ROS1-positive lung cancer.Guests:Alexander Drilon, MDChief, Early Drug Development ServiceAttending Physician, Thoracic Oncology ServiceMemorial Sloan Kettering Cancer CenterProfessor, Weill Cornell Medical CollegeRosario Charo Garcia Campelo, MDHead of Medical Oncology and Thoracic Tumor Unit, Chair, University HospitalHead of the Oncology Research Group, Biomedical Research Institute A Coruna Spain
How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore the latest research, the science driving these innovative approaches, and what these advances could mean for patients and the future of precision oncology.Key Topics Covered:•ALK-positive lung cancer•Cellular Therapy•VaccinesGuests:Vincent Lam, MDAssociate Professor of Oncology, Johns Hopkins University School of MedicineDirector, Thoracic Oncology Clinical Research ProgramSidney Kimmel Comprehensive Cancer CenterCarmen Mecca. PhDPostdoctoral Fellow, Chiarle LabDepartment of PathologyBoston Children’s Hospital
Starting your first faculty position can be both exciting and overwhelming. In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Arthi Sridhar to discuss the transition from fellowship to independent practice, sharing practical insights on navigating clinical responsibilities, building professional relationships, balancing personal and professional priorities, and developing a sustainable career in oncology. Whether you're beginning a career in academic or community practice, this conversation offers actionable advice to help you thrive in your early years as faculty.Guests:Arthi Sridhar, MD - Arthi.Sridhar@UTSouthwestern.edu Assistant Professor, Department of Internal MedicineHarold C. Simmons Comprehensive Cancer CenterUT Southwestern Medical Center
In this episode of Lung Cancer Considered, Dr. Balazs Halmos reflects on a career at the forefront of thoracic oncology, sharing the pivotal moments, lessons learned, and hard truths that have shaped modern lung cancer care.Guest:Balazs Halmos, MD, MSProfessor of MedicineAssociate Director, Clinical ScienceMontefiore Einstein Comprehensive Cancer Center
This episode of Lung Cancer Considered provide a preview of the upcoming IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea this September. Key topics covered includeWCLC26 highlights - Multidisciplinary, WCLC26 deadlines and information about Seoul.Guests:Myung-Ju Ahn, MD, PhDDistinguished ProfessorSection of Hematology-Oncology, Department of MedicineHanyang University Medical Center, Hanyang University School of MedicineSeoul, Republic of KoreaVincent Wentao Fang, MDProfessor, Department of Thoracic SurgeryShanghai East Hospital Tongji University Medical SchoolJiraporn Setakornnukul, MD, PhDRadiation Oncologist, Associate ProfessorDivision of Radiation Oncology Department of RadiologyFaculty of Medicine, Siriraj Hospital Mahidol UniversityBangkok, ThailandYasushi Yatabe, MD, PhDChief, Department of Diagnostic Pathology, National Cancer Center HospitalChief, Division of Molecular Pathology, National Cancer Center Research InstituteNational Cancer Center Japan
In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape.Guests:Julie R. Brahmer, MD, MSc, FASCO, FAIOThe Marilyn Meyerhoff Professor of Thoracic OncologyCo-Leader, Cancer Immunology Research ProgramCo-Director, Upper Aerodigestive Cancers ProgramDirector, Johns Hopkins Kimmel Cancer Center, Bayview CampusProfessor Solange Peters, MD, PhDChair of Medical OncologyDirector of Oncology Department - CHUVLausanne University Hospital
In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages.Guests: Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care. Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO
As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Andrea Fillipi and Dr. Piergiorgio Solli. The tumor board focuses on the management of resectable EGFR-mutant NSCLC. Host: •Alfredo Addeo, MDHead of Oncology ServiceUniversity Hospital GenevaGuests:Andrea R. Filippi, MD Head of Radiation Oncology, Fondazione Istituto Nazionale dei Tumori, MilanAssociate Professor, Radiation TherapyDepartment of Oncology, University of MilanPiergiorgio Solli, MD, PhD Head of Thoracic SurgeryIRCCS Fondazione Istituto Nazionale dei Tumori, Milan
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS updates from the American Association for Cancer Research (AACR) 2026 Annual Meeting with Dr. Deborah Doroshow, Dr. David S. Hong, and Dr. Jonathan Riess.Guests:Deborah Doroshow, MD, PhDAssociate Professor of Medicine, Hematology/OncologyTisch Cancer Institute, Icahn School of Medicine at Mount SinaiDavid S. Hong, MDDouglas E. Johnson Endowed ProfessorDeputy Chair, Department of Investigational Cancer Therapeutics [A Phase I Program]Division of Cancer MedicineClinical Medical Director, Clinical and Translational Research CenterThe University of Texas MD Anderson Cancer CenterJonathan Riess, MDAssociate Professor of Medicine, UC Davis Comprehensive Cancer CenterDirector of Thoracic Oncology, University of California, Davis
This episode of Lung Cancer Considered, part of IASLC’s World Language Series, features host Dr. Narjust Florez leading a Spanish-language discussion with Dr. José Corona-Cruz and Dr. Diego Carrillo on perioperative chemoimmunotherapy in early-stage lung cancer. Using a real-world case, they explore clinical decision-making, biomarker considerations, and surgical challenges, with a focus on implementation barriers in Latin America. The conversation highlights multidisciplinary strategies and practical insights to optimize care in resource-variable settings.
This episode of LCC covers the work of our nursing and allied health professional committee and, most importantly, highlight their role in the care of patients with thoracic malignancies. Guests:Professor Nicole Kiss is a Fellow of Dietitians Australia and Clinical Associate Professor in the Institute for Physical Activity and Nutrition at Deakin University. Nicole co-leads the Exercise and Nutrition for Cancer research group, with her research focused on early identification of cancer-related muscle loss and improving access to treatment.Dr. Morten Quist is a former IASLC Board member and is currently an Associate Professor and Research Physiotherapist at the University Hospital of Copenhagen, Rigshospitalet. For the past 25 years, he has pioneered clinical exercise-based rehabilitation for people living with cancer, with a primary focus on exercise, prehabilitation, and rehabilitation in lung cancer. His work bridges research, clinical care, patient advocacy, and voluntary engagement – always with patient wellbeing at the center.
CEO of Lung Connect India, an initiative dedicated to improving awareness, access, and advocacy in lung cancer care. With a strong commitment to patient-centered innovation, he works to bridge gaps between patients, caregivers, clinicians, and policymakers, advancing meaningful dialogue and practical solutions to improve lung cancer outcomes
As part of IASLC’s ongoing podcast series in world languages, Dr. Chul Kim moderates a discussion in Korean with Dr. Beung-Chul Ahn and Dr. Hyein Jeon. The session focuses on the clinical management of EGFR-mutant non-small cell lung cancer (NSCLC) through a case-based discussion. Guests:
In this episode, recorded in Mandarin, host Dr. Chunxia Su leads a discussion about early stage and preoperative care for patients with NSCLC with an EGFR mutation.Guests:Wenzhao Zhong, Deputy Prensendent of Guangdong Provincial People's Hospital, Director of the Cancer Institute, Guangdong Provincial People's HospitalJie Hu， Deputy director, Department of Respiratory Medicine, Shanghai Geriatric Medical Center，Zhongshan Hospital, Fudan UniversityMin Fan M D， Deputy Director , Department of Radiation Oncology, Fudan University Shanghai Cancer Center
In this episode of Lung Cancer Considered, host Dr. Narjust Florez conducts three mock molecular tumor boards with Dr. Misako Nagasaka and Dr. Biagio Ricciuti, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion addresses the question, “How do we get the right molecular answer, at the right time, for the right patient?” Guests:Misako Nagasaka, MD, PhDAssociate Clinical Professor University of California, Irvine Biagio Ricciuti, MD, PhDThoracic Medical Oncologist, Dana-Farber Cancer InstituteFaculty, Harvard School of Medicine
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guest Dr. Sam Rosner examine controversies around antibody-drug conjugates (ADCs) live from the 2026 Targeted Therapies of Lung Cancer (TTLC) conference. Guest:Sam Rosner, MDAssistant Professor of Medicine, University of Maryland School of MedicineThoracic Medical Oncologist, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Angela Botticella and Dr. Jean Yannis Perentes. The tumor board focuses on the management of resectable EGFR-mutant NSCLC.Guests:Angela Botticella, MDRadiational OncologistDepartment of Radiation OncologyGustave RoussyJean Yannis Perentes, MD, PhDProfessor and Chief, Department of Thoracic SurgeryUniversity Hospital of Lausanne CHUV
In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by Dr. Sara Pilotto and Dr. Jonathan Riess for a virtual tumor board discussion on the management of metastatic EGFR exon 19 NSCLC . Using a complex case featuring discordant biomarker results and brain metastases, the panel explores first-line treatment strategies including osimertinib monotherapy, FLAURA2 (osimertinib plus chemotherapy), and MARIPOSA (amivantamab plus lazertinib), as well as sequencing at progression, re-biopsy, CNS considerations, and the evolving role of local consolidation and clinical trials.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often underrepresented in clinical trials – with Dr. Hina Khan and Dr. Corey Langer, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion examines treatment decision-making in patients with ECOG performance status 2, renal dysfunction, advanced age, and complex comorbid conditions, emphasizing careful phenotyping, geriatric assessment, and individualized risk–benefit evaluation. The episode also highlights the balance between efficacy, toxicity, quality of life, and patient goals when treating the patients most commonly seen in clinical practice. Guests:Hina Khan, MDThoracic OncologistAssistant Professor of MedicineWarren Alpert Medical School, Brown UniversityCorey Langer, MD, FACP Director, Thoracic Oncology, Abramson Cancer CenterProfessor of Medicine , Perelman School of MedicineUniversity of Pennsylvania
Oncology, Thoracic Medical Oncology SectionEmory University Winship Cancer InstituteRajat Thawani, MDAssistant Professor of MedicineDivision of Hematology and OncologyKnight Cancer Institute, OHSU
This episode of Lung Cancer Considered focuses on a case of a patient with extensive stage SCLC. SCLC is a highly lethal subtype of lung cancer, accounting for about 13% of new lung cancer diagnoses with high variability based on geography and socioeconomic factors. The standard treatment for ES-SCLC had been platinum + etoposide for several decades, but over the past 7 years, we have had several new paradigm shifts that have led to real survival gains. To discuss current state of the art management, Guests: Raffaele Califano, Consultant at the Christie and Professor of Medical Oncology at Manchester University in the United Kingdom. Dr. Jessica Menis, thoracic medical oncologist at University Hospital of Verona, in Verona, Italy
This episode examines the role public policy plays in impacting lung cancer treatment and research. The world has made tremendous progress in the treatment of lung cancer over the past decade, and much of that progress is the result of supportive public health policies. As we look to the future, healthcare policy is sure to play an even bigger role in further improving patient outcomes, but many challenging barriers exist on a global scale. Host: Dr. Stephen LiuGuests:Professor Andreas Charalambous, Chair of the Department of Nursing and Professor of Oncology and Palliative Care at the Cyprus University of Technology.Professor Nicole Rankin, Head of the Evaluation and Implementation Science Unit at the Melbourne School of Population and Global Health of the University of MelbourneDr. Samuel Kareff, thoracic medical oncologist at the Eugene M. and Christine E. Lynn Cancer Institute and Clinical Assistant Professor at Florida Atlantic University
As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with two expert cardiothoracic surgeons, Dr. Ben Li, Professor from The First Affiliated Hospital of Guangzhou Medical University and, and Dr. Calvin Ng, Professor from the Chinese University of Hong Kong. The discussion: reviews surgical management of early-stage NSCLC, including VATS, and lobar versus sublobar resection; and explores novel technologies including endobronchial therapy and tubeless anesthesia. Host: Molly Li, MD Clinical Assistant ProfessorDepartment of Clinical Oncology, CUHK, Hong KongGuests: Shuben Li, MD, PhDProfessor, Department of Thoracic SurgeryNational Center for Respiratory MedicineThe First Affiliated Hospital of Guangzhou Medical University Calvin S.H. Ng, BSc MBBS, MDEnvironmental Foundation Professor of Thoracic SurgeryDepartment of SurgeryThe Chinese University of Hong Kong (CUHK)
This episode of Lung Cancer Considered examines how artificial intelligence is being incorporated into patient care and what the future holds for this emerging technology. We will be discussing:•Is AI the right move for oncology care?•What is the impact on patient care and our patient expert’s experience?•And how can we learn more about AI?Guest:Dr. Sandip Patel, is a professor of Medicine at UCSD and a nationally recognized leader in precision cancer medicine and innovation. He specializes in early-phase clinical trials and immunotherapy, with a focus on developing innovative treatments for patients with advanced lung cancer. Today, we’re excited to welcome him to the podcast to discuss the future of AI in cancer care, in general, and in thoracic oncology in particular.
Radiotherapy and Early Phase Clinical Trials Centre, Medical University of Gdańsk in Poland
As part of IASLC’s ongoing series of Lung Cancer Considered podcast episodes in world languages, Dr. Ece Cali moderates a discussion in Turkish with Dr. Irfan Çiçin and Dr. Fulden Yumuk. The episode is part of our Virtual Tumor Board series and focuses on immunotherapy for non-small cell lung cancer (NSCLC).
This episode reviews the IASLC 2025 Hot Topic in Basic and Translational Science Conference, which focused on unraveling precancer and early-stage lung cancer, a theme that really captures where the field is heading. Instead of reacting to advanced disease.Guests: Dr. Triparna Sen, a professor of Internal Medicine at The Ohio State University and the director of the Lung Cancer Preclinical Therapeutics Platform at the OSUCCC – James. She also serves as the associate director of research for the Division of Medical Oncology. Her research focuses on understanding and therapeutically targeting mechanisms of therapy resistance and lineage plasticity in lung cancer, with a primary emphasis on small cell lung cancer (SCLC) and biologically aggressive subsets of non-small cell lung cancer. Dr. Aaron Tan is a physician-scientist whose work bridges early detection, translational biology, and clinical relevance in lung cancer. Dr. Tan is a Medical Oncologist at the National Cancer Centre Singapore (NCCS), where he is involved in early drug development, genomics with a focus on EGFR mutated lung cancer, and clinical implementation of liquid biopsy including for advanced lung cancer and MRD in early-stage lung cancer.
As part of IASLC’s Lung Cancer Considered World Language Series, guest host Dr. Maria Cecilia Mathias leads a discussion in Portuguese about the junior faculty perspective with Dr. Maria Thereza Starling and Dr. Paula Duarte.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by CNN Medical Correspondent Meg Tirrell and WTOP reporter Neal Augenstein to discuss the role of the media in lung cancer awareness and perception. Traditional media, including television and radio, do much to shape the public perception of lung cancer and healthcare in general. Meg Tirrell and Neal Augenstein share their experiences reporting in the health sector, establishing trust with their audiences in the face of uncertainty, and distilling complex medical information to the general public.
Since the first immunotherapy agent for lung cancer was approved in 2015, this class of drugs has captured the imagination and the narrative for the treatment of driver negative lung cancer. Immunotherapy is now the standard of care for most patients with lung cancer in some form. And while not all patients benefit, those that do, have the chance for transformative benefit. In today’s episode, we focus not on the benefit of immunotherapy, which can be massive, but on the toxicity of immunotherapy. Guest: Dr. Jarushka Naidoo, a consultant medical oncologist at Beaumont Hospital Dublin and a Professor in the Royal College of Surgeons in Ireland. She currently serves as national lung cancer lead for Cancer Trials Ireland and serves on several international guideline panels including ASCO and SITC
The FDA has approved subcutaneous amivantamab. Join host Dr. Narjust Florez and guests, Dr. Natasha Leighl and Dr. Federico Cappuzzo, as they explore the science and convenience factor, as well as what this shift means for patients, clinicians, and oncology practice.
In this special episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the IASLC | ASCO 2025 North America Conference on Lung Cancer.Dr. Igor Odintsov discusses updates in diagnostic pathology, including the integration of next-gen sequencing into the patient's journey. Dr. Byoung Chul Cho shares data from the phase 3 trial of gotistobart vs. docetaxel in patients with metastatic squamous cell lung cancer. Dr. Sulin Wu shares insights on the role of family history in lung cancer among women and low-exposure smokers.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with two thoracic oncologists practicing in New Zealand—Dr. Laird Cameron from Auckland Hospital and Dr. Annie Wong from the University of Otago—about the unique challenges and approaches to lung cancer care in their island nation of 5.4 million people. The conversation explores New Zealand's healthcare coverage system, patient population characteristics including smoking rates, the current state of lung cancer screening programs, and how molecular testing is conducted for non-small cell lung cancer patients. Drs. Cameron and Wong discuss access to targeted therapies and immunotherapy, the drug approval process in New Zealand, cultural considerations and health disparities affecting lung cancer treatment, and the clinical research infrastructure available in the country. This global perspective highlights how IASLC members face different regional challenges while working toward common goals in advancing lung cancer care.
As part of IASLC’s Lung Cancer Considered World Language Series, host Dr. Narjust Florez leads a Spanish-language discussion with three leaders in thoracic oncology across Latin America: Dr. Mónica Castro, Dr. Dolores de la Mata, and Dr. Maritza Ramos Ramírez. They discuss the current landscape of lung cancer in women across the region including unique risk factors and social challenges. The guests share their career paths, the barriers women face in thoracic oncology in Latin America, and their advice for the next generation entering the field.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Prof. Li Zhang and Dr. Elaine Shum about recent progress in antibody–drug conjugates (ADCs) for EGFR-mutant non-small cell lung cancer (NSCLC). They discuss new approvals of datopotamab deruxtecan (in the United States) and sacituzumab tirumotecan (in China), key findings from the TROPION and OptiTROP trials, and emerging agents. The conversation highlights the advances in efficacy, safety, and combination strategies that are shaping the evolving treatment landscape for patients with EGFR-mutant NSCLC.Guest: Li Zhang, MDProfessor, Medical Oncology DepartmentSun Yat-Sen University Cancer CenterNo SocialGuest: Elaine Shum, MDAssistant ProfessorDirector of Cancer Screening ProgramsNew York University Perlmutter Cancer Center
As part of IASLC’s Lung Cancer Considered world language series, host Dr. Narjust Florez discusses the role of complementary medicine in cancer care in Spanish with Dr. Cittim Bernardo Palomares and Dr. Eduardo Rios-Garcia. They discuss the role of integrative medicine in lung cancer, how to access accurate information, and the benefits of certain forms of complementary and integrative medicine for patients and their caregivers.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages.In this episode, host Dr. Elene Mariamidze moderates a discussion in Georgian about highlights from the conference with Dr. Salome Begijanashvili, Dr. Beka Shubitidze, and Dr. Mariam Tchiabrishvili.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez speaks with two remarkable young lung cancer advocates Samantha Murell and Megan Flanagan, who are redefining what it means to live with the disease. They share their journeys from diagnosis to advocacy, shedding light on the challenges young patients face, breaking misconceptions, and offering hope to others along the way.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages.In this episode, host Dr. Zsolt Megyesfalvi moderates a discussion in Hungarian about highlights from the conference with Dr. Zsuzsanna Keleman, Dr. Lilla Horvath, and Dr. Gyula Ostoros.
This episode of Lung Cancer Considered covers highlights from the 2025 ESMO Annual Meeting held October 17th to the 21st in Berlin, Germany. Guests are: Dr. Xiuning Le from MD Anderson Cancer Center in Houston, Texas.Dr. Pedro Rocha from Vall d’Hebron University Hospital in Barcelona, Spain.Dr. Riyaz Shah, a consultant medical oncologist at the Kent Oncology Centre in the United Kingdom.
In this episode of Lung Cancer Considered, Dr. Narjust Florez leads a discussion with Ann Fish-Steagall and Amanda Nerstad about the 2025 Lung Cancer Hope Summit. The team discusses highlights from the meeting, including groundbreaking research, innovative treatments, and patient advocacy.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages.In this episode, host Dr. Helena Linardou moderates a discussion in Greek about highlights from the conference with Dr. Foteinos-Ioannis Dimitrakopoulos and Dr. Evangelos Sarris.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of maintenance lurbinectedin plus atezolizumab for extensive stage small cell lung cancer, based on the phase III IMforte trial. Dr. Hossein Borghaei joins the podcast to explain the results and offer perspective on the impact of maintenance therapy for SCLC.Guest:Dr. Hossein Borghaei, DO, MSChief, Division of Thoracic Medical OncologyProfessor, Department of Hematology/OncologyFox Chase Cancer Center
As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Lizza Hendriks moderates a discussion in Dutch with Dr. Marthe Paats and Dr. Gerrina Ruiter on the treatment of EGFR non-small cell lung cancer.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chul Kim moderates a discussion in Korean about highlights from the conference with Dr. Jeongmin Seo and Dr. Min Hee Hong.Guest Host: Chul Kim, MD, MPHThoracic Medical Oncologist and Associate ProfessorGeorgetown UniversityInstagram: @fe0120 Guest Name(s) & Title(s):Jeongmin Seo, MD, MScAssistant Professor, Medical OncologySeoul National University Bundang HospitalMin Hee Hong, MDAssociate Professor, Yonsei Cancer CenterSeverance Hospital, Seoul
This episode of Lung Cancer Considered reviews new and upcoming approvals for subcutaneous immune checkpoint inhibitors. Join host Dr. Narjust Florez and guests, Dr. Cheryl Ho and Dr. Maria Velez Velez, for a discussion of the formulation and its place in the management of patients with lung cancer. Guests:Cheryl Ho, MD, FRCPCThoracic Oncologist, BC CancerClinical Associate Professor and Fellowship Program DirectorUniversity of British ColumbiaMaria Velez Velez, MD, MSClinical Instructor, Division of Hematology/OncologyDavid Geffen School of Medicine at UCLA
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, guest host Dr. Kuan Yu Chen moderates a discussion in Mandarin with Dr. Bin-Chi Liao and Dr. Jeng-Sen Tseng, leading lung cancer experts in Taiwan, who share their perspectives on key highlights from the conference.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages.In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about highlights from the conference with Dr. Clarissa Baldotto, Dr. Lilian Faroni, Dr. Maria Cecilia Mathias, and Dr. William William, Jr.
In this episode, recorded live in Spanish at WCLC 2025, Dr. Diego Carrillo reflects on his experiences as a junior faculty member at WCLC 2025.In conversation with host Dr. Narjust Florez, they discuss conference activities, research highlights, and how WCLC helps junior faculty build their networks and shape the future of lung cancer care and research.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Alona Zer moderates a discussion in Hebrew about highlights from the conference with Dr. Haitam Nasrallah, Dr. Jair Bar, and Dr. Ory Wiesel.
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the conference. Dr. Susan Scott discusses EGFR mutant NSCLC and results from PALOMA-2 and subcutaneous amivantamab. Dr. Wenfeng Fang discusses Iza-Bren (BL-D01D1), a first-in-class EGFR x HER-3 biospecific ADC linked to a novel topoisomerase I inhibitor payload, with promising preliminary activity in EGFR positive previously treated NSCLC. Dr. Biagio Ricciuti shares his insights from WCLC 2025, including the FLAURA-2 OS readout, the HARMONi trial in EGFR positive NSCLC, and his research in the use of immunotherapy in early-stage lung cancer.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Narjust Florez moderates a discussion in Spanish about highlights from the conference with Dr. Laura Mezquita and Dr. Jorge Alatorre Alexander.
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. Tina Cascone discusses results from the NADIM ADJUVANT Phase III trial. Dr. Jacie Jiaqi Law shares survival outcomes of VATS compared to open lobectomy, and Dr. Corinne Faivre-Finn and Dr. Shankar Siva summarize results from the EA5181 trial of concurrent and consolidation durvalumab after chemoradiation for unresectable NSCLC and hypofractionation vs conventional fractionation for LS SCLC.
The 2025 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2025 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin Chinese about highlights from the conference with Dr. Yang Xia and Dr. Nan Bi.
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. David Planchard discusses the data that we all were waiting for the FLAURA-2 overall survival. Dr. Alexander Drilon shares results from the ARROS-1 study including efficacy results and safety data for zidesamtinib, a new ROS1 inhibitor that could change the landscape in the ROS1 space.
In this episode of Lung Cancer Considered, Dr. Narjust Florez and Dr. Stephen Liu share tips for first-time attendees of the World Conference on Lung Cancer (WCLC). Recorded live at WCLC 2025, hear their 10 key recommendations to make the most of your experience, including advice on how to sneak self-care into your busy conference schedule.
LCC in Mandarin: Neoadjuvant and Perioperative Therapy for Locally Advanced NSCLC by IASLC
Lung Cancer Considered--STK11 and KEAP1 as resistance mechanisms to immunotherapy by IASLC
As part of IASLC’s ongoing series of podcasts in world languages, Dr. Nagla Abdel Karim moderates a discussion in Arabic with Dr. Asrar AlAhmadi and Dr. Maya Khalil. The group discusses the journey and career development of Arabic women in the field of thoracic oncology.
LCC in Romanian: Management of Unresectable, EGFR-mutated Stage III Lung Cancer in Romania by IASLC
On December 5, 2025, we will kick off the IASLC ASCO 2025 North America Conference on Lung Cancer. Guest include Dr. Ramesh Rengan, the Peter Wootton Professor and Chair of Radiation Oncology at the University of Washington and Senior Vice President of the Fred Hutchinson Cancer Center and Dr. Kristen Marrone, Associate Professor of Oncology and Director of the Medical Oncology and Hematology Fellowship Program at Johns Hopkins University.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Chunxia Su and Dr. Collin Blakely. The case explores resectable EGFR NSCLC.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for NSCLC with a ROS1 gene fusion. Dr. Enriqueta Felip and Dr. Jorge Nieva join the conversation to help review the data and offer help place this new agent in the proper perspective.
ASCO 2025 HighlightsGuests:Charu Aggarwal, MD, MPHLeslye M. Heisler Professor of MedicineSection Chief, Thoracic and Head & Neck CancerAssociate Director, Penn Center for Cancer Care Innovation (PC3I)University of Pennsylvania Patrick Forde, MBBChAssociate ProfessorJohns Hopkins University
In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new agent, I am joined by two expert thoracic oncologists. I want to welcome Dr. Mor Moskovitz, Head of the Thoracic Medical Oncology Service at Davidoff Cancer Center at the Rabin Medical Center in Petah Tikva, Israel.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Mihaela Aldea about the key information about RET-positive NSCLC, from diagnostic challenges to treatment selection. Join us in this lively discussion.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Eric Singhi and Dr. Misty Shields about patient education and communication. Tune in to hear the top things to discuss during your first oncology visit, including conflict and miscommunication resolution.
Guest: Dr. Corey Langer is the Director of Thoracic Oncology and Professor of Medicine at the Hospital of the University of Pennsylvania
Host: Ece Cali Daylan, Assistant Professor of Medicine, Division of Oncology at Washington University School of MedicineGuest: Saadettin KilickapGuest: Ozden Altundag
This episode of Lung Cancer Considered takes an in-depth look at thymoma and thymic carcinomas, both challenging diseases to treat with evolving new therapeutics. Join host Dr. Narjust Florez and guests, Dr. Claudia Proto and Dr. Kim Chul, for a discussion of these understudied and potentially poorly understood diseases.
As part of IASLC's ongoing series of podcasts in world languages, Dr. Balazs Halmos moderates a discussion in Hungarian with Dr. Krisztina Bogos, Dr. Ferenc Rényi-Vámos and Dr. Zsolt Megyesfalvi. The podcast reviews recent advances in lung cancer screening, diagnosis and management with a particular focus on implementation in Hungary. Highlights of the discussion include novel staging and diagnostic tools, state-of-the-art biomarker testing, perioperative therapy and clinical trials access.Host: Balazs Halmos, MD, Director, Thoracic Oncology & Clinical Cancer Genomics, Montefiore Medical Park at Eastchester, Bronx, New YorkGuest: Ferenc Rényi-Vámos, MD, PhD, Thoracic Surgery, Semmelweis University and National Institute of Oncology, Budapest, HungaryGuest: Krisztina Bogos, MD, Thoracic Oncology National Koranyi Institute of Pulmonology, Budapest, Hungary Lung Cancer Research and PathologyGuest: Zsolt Megyesfalvi, MD, PhD, Semmelweis University and National Institute of Oncology, Budapest, Hungary and National Koranyi Institute of Pulmonology, Budapest, Hungary
The 2024 World Conference on Lung Cancer brought together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages.In this episode, host Dr. Sally Lau moderates a discussion in Cantonese Chinese about highlights from the conference with Dr. David Lee and Dr. Molly Li.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez engages in a discussion with patient advocate Summer Farmen. Listen to the episode to learn about Summer’s journey through diagnosis and treatment, and the importance of patient advocate groups. •Summer FarmenALKtALK Program CoordinatorBoard Member, ALK Positive, Inc.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on how small cell lung cancer continues to evolve with new treatment options and recent FDA approval. Listen to the episode to learn about the current standard of care and future therapies with a brief discussion about small cell transformation.Guest: Triparna Sen, MDAssociate ProfessorDirector, Lung Cancer PDX Program, Icahn School of Medicine at Mount SinaiGuest: Jacob Sands, MDAssistant Professor of Medicine, Harvard Medical SchoolLowe Cancer Center for Thoracic OncologyDana Farber Cancer Institute
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of two of the most challenging thoracic malignancies – NUT carcinoma and mesothelioma. Listen to the episode to learn about the role of next-generation sequencing in diagnosis and treatment selection, as well as current and future targeted therapy in the management of both. GuestsMelina Marmarelis, MD MSCEAssistant Professor Medical Director, UPenn MesotheliomaUniversity of PennsylvaniaJia Luo, MDMedical Oncologist, Thoracic Oncology Program, Dana-Farber Cancer InstituteFaculty, Brigham and Women's Hospital and Harvard Medical School
Descriptions: As part of the IASLC's ongoing series of podcasts in world languages, Dr. Nagla Abdel Karim moderates a discussion in Arabic with Dr. Bashir Abu Aqeel and Dr. Fawzi Abu Rous. The group discusses chemoimmunotherapy in metastatic non-small cell lung cancer.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case involving drug resistance in EGFR mutant NSCLC. This discussion takes the listener through the treatment of EGFR mutant NSCLC after acquired resistance to osimertinib. Guest: Dr. Yasushi Goto from National Cancer Center, Japan in TokyoGuest: Dr. Rachel Sanborn, the Earle A. Chiles Research Institute of the Providence Cancer Institute in Portland, Oregon
This episode of Lung Cancer Considered covers the recent FDA approval of Osimertinib after chemo-radiation in EGFR positive NSCLC based on the LAURA trial which was presented at the 2024 ASCO Annual Meeting. Host Dr. Narjust Florez goes in depth with podcast guest Dr. Pamela Samson about the LAURA Trial and its implications for patients and clinicians. Guest: Dr. Pamela Samson is an assistant professor in the Department of Radiation Oncology at Washington University in St. Louis. Dr. Samson specializes in the care of thoracic malignancies and ways to deliver appropriate radiation therapy without compromising efficacy and diminishing toxicities.
En este episodio de Lung Cancer Considered, vamos a hablar sobre el cancer de pulmón en México. Tengo el placer de tener en este episodio dos doctores con mucha experiencia tratando y entendiendo las necesidades de los pacientes con cancer de pulmón en México. Este episodio es una introducción y esperamos tener conversaciones as profundas en el futuro. Bio: Tenemos al Dr. Jorge Alatorre, Oncology clínico con Alta especialidad en Tumores del Tórax (Cáncer de pulmón y Mesotelioma). Y es jefe del Servicio de Oncología Médica del Instituto Nacional de Enfermedades Respiratorias (INER). También ofrece consulta en el Centro Médico ABC Santa Fe y en ONCARE ubicados en la Ciudad de MéxicoBio: Dr. Silviano Rios, Cirujano torácico de la ciudad de Monterrey en México. Atiende a sus pacientes en el Hospital Zambrano Hellion y TecSalud y se especializa en cirugía mínimamente invasiva.
Description: As part of IASLC’s commitment to communicating in all world languages, this episode of Lung Cancer Considered is recorded in German and is part of our Virtual Tumor Board series. Host Professor Alessandra Curioni-Fontecedro moderates a discussion with two colleagues, who will discuss the dynamic topic of managing resectable stage III NSCLC. Host: Prof Alessandra Curioni-Fontecedro, MD, Head of Oncology, Cantonal Hospital Fribourg, Chair of Medical Oncology, University of FribourgGuest: Prof. Isabelle Opitz, Professor of Thoracic Surgery and Director of the Department of Thoracic Surgery at University Hospital of Zurich, Chair of the Lung Cancer Center of Zurich, and the past President of the European Society of Thoracic Surgery. She received the IASLC Robert J Ginsberg Lectureship Award for Surgery at the 2022 World Conference on Lung CancerGuest: Prof. Michael Thomas, Chefarzt of Dept of Thoracic Oncology at the Thoraxklinik Heidelberg, Germany.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of zenocutuzumab for NSCLC with an NRG1 fusion. NRG1 fusions are rare but important events seen in many cancer types, including NSCLC. Zenocutuzumab is a HER2/HER3 bispecific antibody that showed clear efficacy in NSCLC and in pancreatic cancer that harbored an NRG1 fusion.Guest: Dr. Alison Schram, Assistant Attending Physician and Section Head of Oral Therapeutics in Early Drug Development at Memorial Sloan Kettering Cancer Center in New York
ESMO Immuno-Oncology Congress 2024 HighlightsDescription: In this episode of Lung Cancer Considered, host Dr. Narjust Florez and Dr. Alfredo Addeo discuss some of the data presented at The ESMO Immuno-Oncology Congress 2024, which took place in December 2024 in Geneva, Switzerland.Guest: Dr. Alfredo Addeo, Professor and Chief of Oncology, University Hospital of Geneva
Preview: 2025 Pan-Africa Lung Cancer MeetingThe 2025 Pan-Africa Lung Cancer Conference will take place January 31 - February 1, 2025, in Accra, Ghana and represents the first IASLC multidisciplinary lung cancer conference in Sub-Saharan Africa. In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks with the conference co-chairs about this groundbreaking meeting and what attendees will experience at the meeting.Guest: Dr. Chukwumere E. Nwogu is a Professor of Surgery at Roswell Park Cancer Institute and the University at Buffalo Jacobs School of Medicine & Biomedical SciencesGuest: Dr. Jane Sandra Afriyie-Mensah is a Senior Pulmonologist and a Distinguished Academic and Researcher, currently affiliated with the University of Ghana and Korle Bu Teaching Hospital.X: NA
Lung Cancer Considered host Dr. Stephen Liu and two distinguished thoracic oncologists review the highlights from the recently completed ESMO Asia 2024 meeting, held in Singapore. The episode covers a number of trials, including an update on FLAURA2, TROPION-Lung01 and TROPION-Lung05, ALESIA, and PACIFIC 5.Guest: Dr. Misako Nagasaka, Associate Professor from the University of California, IrvineGuest: by Dr. Molly Li, Clinical Assistant Professor from Chinese University of Hong Kong.
Tumor Treating Fields (TTFields) is a non-invasive cancer treatment that uses alternating electric fields to disrupt the ability of cancer cells to divide. TTFields can slow down tumor growth and spread, and may help people live longer than chemotherapy alone. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses this new therapy and the Phase III LUNAR study that led to its FDA approval. Guest: Dr. Ticiana Leal is an Associate Professor and serves as Director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of perioperative nivolumab based on the Phase III CheckMate 77T study. Perioperative therapy has improved outcomes in patients with resectable NSCLC and is emerging as best practice but there is nuance to the delivery of this therapy.Guest: Dr. Tina Cascone is a Physician-Scientist and Associate Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas and lead author of the CheckMate 77T manuscript in the New England Journal of MedicineGuest: Dr. Shun Lu is the Chief of Shanghai Lung Cancer Center and Shanghai Chest Hospital and Professor at Shanghai Jiaotong University. He is an executive board member of the Chinese Society of Clinical Oncology and past chair of Chinese Lung Cancer Association
In this episode of Lung Cancer Considered host Dr. Narjust Florez discusses the future of lung cancer research in Brazil and the largest lung cancer screening program in South America. The episode was recorded during the IASLC 2024 Latin America Conference on Lung Cancer held in Bogota, Columbia.Guests: Clarissa Baldotto is a Medical ) Oncologist at D’Or Rio De Janeiro and President Elect for the Brazilian Society of Clinical Oncology (SBOC) Guest: Dr. Francisco Sarmento is a Thoracic Radiologist from Hospital Royal Portuguese in Brazil.
Lung Cancer Considered host Dr. Narjust Florez and Dr. Suresh Ramalingam discuss the recent FDA approval of osimertinib after chemo-radiation in EGFR positive NSCLC. The approval was based, in part, on the results of the LAURA trial, which was presented at the 2024 ASCO Annual Meeting. Guest: Dr. Suresh Ramalingam is the Executive Director, Winship Cancer Institute of Emory University, the Roberto C. Goizueta Distinguished Chair for Cancer Research, and a professor of medicine at Emory University School of Medicine. He is also the editor in chief for the Cancer Journal.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu and guests preview the publication of the Ninth Edition of Tumor, Node and Metastasis (TNM) Classification System for lung cancer. The new edition will be published in January 2025 and has some important changes that reflect an evolving understanding of the disease and more rigorous analysis of data from around the world.Guest: Dr. Valerie Rusch is a Thoracic Surgeon from Memorial Sloan Kettering Cancer CenterMSKCC where she is Vice Chair for Clinical Research in the Department of Surgery and the Miner Family Chair in Intrathoracic Cancers. She has held many leadership positions in the American College of Surgeons and other organizations and was part of the team to first described EGFR mutations. She has been chair of the Thoracic Committee for the American Joint Committee on Cancer 6th, 7th, 8th, and now 9th Editions of the Cancer Staging HandbookGuest: Dr. Hisao Asamura is a Professor of Surgery, Chief of Division of Thoracic Surgery at Keio University School of Medicine in Tokyo, Japan and Vice President of the Japan Lung Cancer Society. For IASLC, he is the Chair of the Staging and Prognostic Factors Committee, former Executive Board Director, and Congress President for the 18th World Conference on Lung Cancer.Guest: Dr. Enrico Ruffini is a Thoracic Surgeon and Professor of Thoracic Surgery from the University of Torino, Italy where he is the Chief of the Thoracic Surgery Unit and Director of the Thoracic Surgery Residency Program. He is heavily involved in the European Society of Thoracic Surgeons and Chair of the IASLC Staging and Prognostic Factors Committee – Thymic domain.
Description: Join us for an engaging discussion on groundbreaking research from investigators across Latin America, featuring insights from large lung cancer screening programs in Mexico and real-world data from the FLAURA-2 study.Titulo: Únete a nosotros para discutir nuevos datos e interesantes presentados por investigadores emergentes en América Latina, desde grandes programas de detección temprana de cáncer de pulmón en México hasta datos del mundo real de FLAURA-2.Guest: Dr. Sergio Mejia – Oncologo clínico de la Fundación Instituto de Cancerología en Bogota, Colombia presento Datos del mundo real usando FLAURA-2Guest: Dr. Luis Leonardo Rojas – Jefe Unidad Funcional GU y Tórax, Fundación CTIC-Luis Carlos Sarmiento Angulo, Bogota Colombia presento sobre el beneficio económico de tener estudios clínicos en Colombia para los canceres mas comunes Guest: Dra. Marisol Arroyo, pulmonologa del instituto de cancerología en la ciudad de Mexico. Discutió con nosotros los programas de detección temprana para el cancer de pulmón en Mexico
Lung cancer breakthroughs, practice updates, and key meetings made 2024 one of the most consequential years in recent memory for lung cancer researchers and clinicians. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu reviewed important meetings and significant clinical trials from 2024 in this special episode.
In this episode of Lung Cancer Considered, Dr. Aakash Desai moderates a discussion in Hindi on management of non-small cell lung cancer and small cell lung cancer in the Indian context. The group discusses advances in immunotherapy in resectable NSCLC and other new treatments on the horizon.Host: Dr. Aakash Desai is an Assistant Professor of Medicine at the O'Neal Comprehensive Cancer Center, University of Alabama in Birmingham, Alabama. He is the Co-Chair, Lung Cancer Working Group, and Associate Director, Phase 1 and Precision Oncology Program.Guest: Dr. Navneet Singh is a Professor, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education & Research (PGIMER) in Chandigarh, India.Guest: Dr. Sewanti Limaye is the Director of Medical & Precision Oncology and Director of Clinical and Translational Oncology Research at the Sir HN Reliance Foundation Hospital and Research Centre in Mumbai, India. She is the Co-Chair of the Asia Pacific Coalition Against Lung Cancer.
Description: As the incidence of lung cancer in those under age 35 increases, oncologists are finding that pregnancy is a central issue for many young women who are coping with lung cancer. In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guests discuss some of the critical issues facing women with lung cancer who are pregnant, or attempting to start a family.Guest: Dr. Ross Camidge is a Thoracic Medical Oncologist and the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado.Guest: Dr. Martina Imbimbo is a Thoracic Medical Oncologist at the IOSI Oncology Institute of Southern Switzerland where she specializes in immunooncology and targeted therapy.
The Power of Movement: Exercise and Lung Cancer-- a Conversation with Experts Description: In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion about the role exercise plays in complementing cancer treatment and how clinicians can work with patients to add regular exercise to their daily regimen.Guest: Dr. Morten Quist is an associate professor at Copenhagen University and a Physiotherapist Clinician-Researcher with 20 years expertise prescribing exercise for patients with cancer at the University Hospital of Copenhagen (Rigshospitalet). He is the Co-founder of the “Body and Cancer” and Founder of the EXHALE programs.Guest: Nancy Campbell is a Clinical Exercise Physiologist in the Zakim Center at Dana-Farber Cancer Institute, and she is a Certified ACE Personal Trainer, and has earned the American College of Sports Medicine Cancer Exercise Trainer Certification.Guest: Dr. Paulo Bergerot is a Medical Oncologist at Oncoclinicas in Brazil, where he specializes in GU malignancies, and focuses on research in the area of exercise and cancer. He has created a remote exercise program for cancer survivors.
Title: IASLC Hot Topic Meeting on Tolerance and Resistance to Targeted Therapy in NSCLC (recorded on 10/21)Description: In this episode of Lung Cancer Considered, host Dr. Stephen Liu previews the upcoming IASLC Hot Topic Meeting on Tolerance and Resistance to Targeted Therapy in NSCLC. To discuss this exciting new meeting and this topic, he is joined by the four co-chairs of the meeting. To learn more about the meeting, visit https://www.httr2024-iaslc.org/.Guest: Dr. Alice Berger is an Associate Professor in the Human Biology Division and the Herbold Computational Biology Program at the Fred Hutchinson Cancer Center at the University of Washington in Seattle, Wash.X: @aliceb_phdGuest: Dr. Kenichi Suda, Associate Professor in the Division of Thoracic Surgery at Kindai University School of Medicine in Osaka, Japan. X: NAGuest: Dr. Montse Sanchez-Cespedes is the Group Leader at the Josep Carreras Research Institute, in Badalona, SpainX: @CespedesMontseGuest: Dr. William Lockwood, Senior Scientist in Integrative Oncology at the BC Cancer Research Institute and Associate Professor in Pathology & Laboratory Medicine at the University of British Columbia in Vancouver, CanadaX: @WWL_18
As part of the IASLC's ongoing series of podcasts in world languages, this episode brings together two leading lung cancer experts who discuss training and education in medical oncology and lung cancer in Arabic.Host: Dr. Nagla Abdel KarimThoracic Medical Oncologist, Director of Developmental Therapeutics at Inova Schar Cancer InstituteProfessor of Medicine at the University of Virginia School of MedicineGuest: Dr. Rami Manochakian, FASCOAssociate Professor of Medicine and Consultant, Thoracic OncologyMayo Clinic Florida
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a discussion about the management of relapsed SCLC, which remains a very challenging cancer to treat, despite recent progress. Guest: Dr. Malinda Itchins is a Medical Oncologist at Royal North Shore Hospital, Visiting Medical Officer for Thoracic Cancers at Chris O’Brien Lifehouse, and Faculty at the University of Sydney. She is the Board Director and Lung Cancer Chair for the Clinical Oncology Society of Australia (COSA) and the Scientific Committee Advanced NSCLC Group Co-Chair for the Thoracic Oncology Group of Australasia (TOGA).Guest: Dr. Jacob Sands is an Assistant Professor at Harvard Medical School and Thoracic Medical Oncologist at the Lowe Center for Thoracic Oncology at the Dana Farber Cancer Institute, where he leads the Clinical Research Program in SCLC. Jacob is also Co-founder and President of the Rescue Lung Society, a 501(c)3 society focused on advancing lung cancer screening.
The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Nagla Abdel Karim moderates a discussion in Arabic about highlights from the conference with Dr. Fawzi Abu Rous, Dr. Raid Aljumaily, Dr. Abdulaziz AlJassim, and Dr. Ashraf Mohamed.Host: Dr. Nagla Abdel KarimThoracic Medical Oncologist, Director of Developmental Therapeutics at Inova Schar Cancer InstituteProfessor of Medicine at the University of Virginia School of MedicineGuests:Dr. Fawzi Abu RousThoracic Medical OncologistHenry Ford Health, Detroit, MIDr. Raid AljumailyAssociate Professor of MedicineUniversity of OklahomaDr. Abdulaziz AlJassim Senior Specialist in Thoracic Medical Oncology and Internal Medicine. Kuwait Cancer Control Center, KuwaitDr. Ashraf MohamedDirector of Surgery Business Development Siemens Healthineers
This episode of Lung Cancer Considered covers the recently completed 2024 ESMO Congress in Barcelona. Host Dr. Stephen Liu discussed the important research presented at the meeting with Dr. Marina Garassino and Dr. Federico Cappuzzo.
In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discuss the recent FDA approval of pembrolizumab plus platinum and pemetrexed for mesothelioma, based on the phase III KEYNOTE 483 study.Guest: Dr. Ibiayi Dagogo-Jack is a thoracic oncologist from Massachusetts General Hospital and Assistant Professor at Harvard Medical SchoolGuest: Dr. Quincy Chu is a thoracic oncologist at the University of Alberta Cross Cancer Institute’s New Drug Development Program and CCTG Investigational New Drug Committee Chair
In this episode of Lung Cancer Consider, host Dr. Stephen Liu previews the upcoming IASLC 2024 Asia Conference on Lung Cancer with meeting co-chair, Dr. Feng-Ming (Spring) Kong.
Description: The FDA approved amivantamab therapy for EGFR mutant NSCLC after progression on osimertinib. This approval is based on the phase III MARIPOSA-2 trial, with data first shared at ESMO 2023 in Madrid with a simultaneous publication in the Annals of Oncology. Lung Cancer Considered host Dr. Stephen Liu talks with two leading oncologists to learn more about how this therapy will be used by cliniciansGuest: Dr. Karen Reckamp, Professor of Medicine, Director of the Division of Medical Oncology, and Associate Director of Clinical Research at Cedars-Sinai Medical CenterGuest: Dr. William Nassib William, National Leader of Thoracic Oncology at Oncolinicas, Sao Paulo, Brazil
The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about highlights from the conference with Dr. Isabella Favato Barcelos and Dr. William Nassib William.Guests:Dr. Clarissa MathiasMedical Oncologist at Oncoclinicas Bahia and Hospital Santa Izabel Dr. Isabella Favato BarcelosMedical Oncologist, Oncoclinicas&Co/MedSir, BrazilDr. William Nassib WilliamNational Leader of Thoracic Oncology at Oncolinicas, Sao Paulo, Brazil
In this special episode of Lung Cancer Considered, Stephanie McDonald and Jillian Thompson discuss their perspectives of attending the 2024 World Conference on Lung Cancer as nurse practitioners.Hear their favorite sessions, their observations as first-time attendees, and why they hope to see more nurse practitioners at future IASLC events.Guests:Jillian Thompson, MSN, ANP-BC, AOCNPNurse PractitionerMedStar Georgetown University HospitalLombardi Comprehensive Cancer CenterStephanie McDonald RN, MSN, FNP-BC, AOCNPNurse PractitionerDana-Farber Cancer Institute
The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Coral Olazagasti moderates a discussion in Spanish about highlights from the conference with Dr. Maria Velez and Dr. Rossana Ruiz.Guests:Dr. Coral OlazagastiAssistant Professor at the Sylvester Cancer Center, University of Miami at Miami, Florida.Dr. Rossana RuizMedical Oncologist from Universidad Peruana Cayetano Heredia Global Health Fellowship at MGH in Boston, MassachusettsThoracic Medical Oncologist, Instituto Nacional de Enfermedades Neoplasicas and AUNA-Oncosalud in Lima, PeruDr. Maria VelezClinical Instructor, Division of Hematology-OncologyUCLA David Geffen School of Medicine in Los Angeles, California
In this special WCLC 2024 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap the conference and discuss the meeting's most impactful research.Dr. Jacob Sands discusses overall survival updates from TROPION-Lung01 with datopotamab deruxtecan and DeLLphi-301 with tarlatamab. Dr. Hidehito Horinouchi reports results from the LUMINOSITY study of telisotuzumab vedotin, and Dr. Noemi Reguart gives some perspective on TRUST-II with talectrectinib. The group discusses the biggest stories from WCLC 2024, their favorite moments, and a preview of WCLC 2025 in Barcelona, Spain.Guests:Dr. Hidehito HorinouchiAssistant Chief, Department of Thoracic Oncology, National Cancer Center Hospital, TokyoGeneral Secretary, Japan Clinical Oncology GroupDr. Noemi ReguartClinical Professor at the University of Barcelona Coordinator of the Thoracic Oncology Unit, Hospital Clínic Barcelona, SpainWCLC 2025 Co-ChairDr. Jacob SandsAssistant Professor of Medicine, Harvard Medical SchoolLowe Cancer Center for Thoracic OncologyDana Farber Cancer Institute
The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin about highlights from the conference with Dr. Huijuan Wang and Dr. Lin Wu.Guests:Dr. Chunxia SuProfessor of Oncology at Tongji University Deputy Director of Medical Oncology at Shanghai Pulmonary HospitalDr. Huijuan WangProfessor of Oncology Department of Medical OncologyThe Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital Dr. Lin WuDirector, Thoracic Oncology Department IIHunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Narjust Florez discusses daily highlights from the conference.Dr. Xiuning Le reports updated results of BAY 292708, and Dr. Gerrina Ruiter summarizes the Beamion LUNG-1 study, both of which evaluate the efficacy of therapies for patients with HER2-Mutant NSCLC. Dr. Fiona Hegi-Johnson adds her perspective as a discussant of the POLESTAR trial evaluating EGFR therapy after chemoradiation in stage III unresectable NSCLC. Guests:Dr. Fiona Hegi-JohnsonRadiation Oncologist at the Peter MacCallum Cancer CentreSenior Research Fellow at the University of MelbourneDr. Xiuning Le, M.D., Ph.D.Assistant Professor in the Department of Thoracic/Head and Neck Medical OncologyUniversity of Texas M.D. Anderson Cancer CenterDr. Gerrina Ruiter, M.D., Ph.D.Pulmonologist Specialized in Thoracic Oncology at the Netherlands Cancer InstituteAmsterdam, The Netherlands
The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Chul Kim moderates a discussion in Korean about highlights from the conference with Dr. Jeongmin Seo and Dr. Jii Bum (Joy) Lee.Guests:Dr. Chul Kim, MDAssociate Professor at Georgetown University with a focus on thoracic oncologyDr. Jeongmin Seo, MDClinical Assistant Professor at Seoul National University Bundang Hospital with a focus on thoracic oncologyDr. Jii Bum (Joy) Lee, MD, PhDYonsei Cancer Center, Yonsei University College of Medicine
In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Stephen Liu discusses daily highlights from the conference.Dr. Caicun Zhou discusses the results of ivonescimab versus pembrolizumab in the first-line HARMONi-2 study. Dr. Tina Cascone discusses preliminary outcomes from the perioperative NeoCOAST-2 study, and Dr. Marina Chiara Garassino outlines the potential QCS-NMR TROP2 biomarker using data from TROPION-Lung01. Dr. Matthew Smeltzer shares the results of the 2024 IASLC Global Survey on Biomarker Testing and how they compare to findings from the previous survey in 2018.Guests:Dr. Tina CasconePhysician-Scientist and Associate Professor, Department of Thoracic/Head and Neck Medical OncologyUniversity of Texas MD Anderson Cancer Center in Houston, TexasDr. Marina Chiara GarassinoDirector, Thoracic Oncology Program and Professor of MedicineUniversity of ChicagoDr. Matthew SmeltzerAssociate Professor, Division of Epidemiology, Biostatistics, and Environmental HealthUniversity of MemphisProfessor Caicun ZhouChief Physician and Director of the Department of Medical OncologyTongji University in Shanghai Pulmonary Hospital
Description: To celebrate IASLC’s 50th Anniversary, IASLC produced podcasts looking at our past and present. In this podcast, host Dr. Narjust Florez peers into the future with a detailed discussion of the new IASLC Strategic Plan and how it will impact IASLC as well as the future of lung cancer care.Guest: Dr. Nick Pavlakis is a thoracic medical oncologist and professor of medicine at the University of Sydney.Guest: Dr. Gilberto Lopes is the Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, Associate Director for the Cancer Center and Medical Director for International Affairs and Professor of Medicine at the University of Miami.
Description: This year marks the 50th anniversary of the International Association for the Study of Lung Cancer and as part of this celebratory year, we are looking at the past, present and future of the organization. In this episode of Lung Cancer Considered, host Dr. Stephen Liu and guests focus on IASLC today – and some of the ongoing efforts of the IASLC and its members.Guest: Dr. Christian Rolfo, Professor of Medicine, Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at the Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University.Guest: Janet Freeman-Daily, Patient Research Advocate, Co-Founder and President of The ROS1ders, former Associate Editor of IASLC Lung Cancer News and co-developer of the IASLC STARS program.Guest: Dr. Emily Stone is a Consultant Respiratory Physician at St. Vincent’s Hospital in Sydney Australia, conjoint Professor at the University of New South Wales, past Chair of the IASLC Tobacco Control and Smoking Cessation Committee, Deputy Chair Thoracic Oncology Group of Australasia and current Editor in Chief of the JTO Clinical and Research Reports
In 1972, in response to the overwhelming need for collaboration and a growing concern for public health, Drs. David T. Carr, Oleg S. Selawry, Lawrence Broder, Clifton Mountain and George Higgins began building an international, multidisciplinary organization. In 1974, the group launched the International Association for the Study of Lung Cancer (IASLC) at their first formal meeting in Florence, Italy, having recruited more than 250 founding members from across the globe and with different perspectives. In today’s episode, host Dr. Narjust Florez talks with two of those early members who played influential roles in IASLC’s early growth and success: Dr. Paul Bunn and Dr. Fred Hirsch.Guest: Dr. Paul Bunn is a Distinguished Professor of Medicine and James Dudley Chair in Cancer Research, Division of Medical Oncology at the University of Colorado School of Medicine. Dr Bunn was President of the ASCO and he served as president and as CEO, of the International Association for the Study of Lung Cancer. Guest: Dr. Hirsch is the Executive Director at the Center for Thoracic Oncology in The Tisch Cancer Institute at Mount Sinai (TCI) and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. Dr. Hirsch served as Chief Executive Officer of IASLC for five years.
Description: On August 19th, the Food and Drug Administration approved lazertinib in combination with amivantamab for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks with Dr. Julia Rotow about this therapy and the MARIPOSA trial, which evaluated the use of lazertinib in combination with amivantamab..Guest: Dr. Julia Rotow, Clinical Director of the thoracic oncology group at Dana-Faber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School.
As part of IALC's ongoing series of podcasts in world languages, this podcast brings together four of the leading Chinese lung cancer experts who discuss current research and clinical issues, in Mandarin.Host: Chunxia Su, M.D., PhD, Professor of Oncology, Doctoral Supervisor, School of Medicine, Tongji UniversityGuest: Xiuning Le, MD, Department of Thoracic-Head & Neck Med Oncology, Division of Cancer Medicine, MD AndersonGuest: Jianming Ying, Professor & Director Department of Pathology National Cancer Center/Cancer Hospital, Chinese Academy of Medical SciencesGuest: Professor Li Zhang, Director of the Department of Internal Medicine, Doctoral Supervisor, Second Class Professor, and Chief Expert on Lung Cancer at Sun Yat sen University Cancer Prevention and Treatment Center
Description: In this episode of Lung Cancer Considered, host (and WCLC 2024 Co-Chair) Dr. Narjust Florez previews the upcoming IASLC 2024 World Conference on Lung Cancer with the meeting’s other three co-chairs. Guest: Dr. Linda Martin, Professor of Surgery and Chief of Thoracic Surgery at the University of Virginia. Guest: Dr. Fabio Ynoe de Moraes, Chief of Global Radiation Oncology and Associate Professor of Radiation Oncology at Queen University. Guest: Dr. Sandip Patel, Professor of Medicine and Thoracic Medical Oncologist at the University of California San Diego.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion in Spanish about perioperative chemotherapy and immunotherapy and how recent research may affect clinical decision making in Latin America.Guest: Dr. Clarissa Baldotto graduated from the Fluminense Federal University and studied Clinical Oncology at the National Cancer Institute (INCA). She completed a Master's Degree in Clinical Cancerology at INCA and a PhD in Medical Sciences at the D'Or Institute for Research and Education (ID'Or).Guest: Dr. Paula Ugalde Figueroa graduated from the School of Medicine at the Federal University of Bahia in Salvador, BA, Brazil. With training in Brazil, the United States, and Canada, Dr. Ugalde has established herself as a research-driven thoracic surgeon. In 2021, she was appointed as a Director of the IASLC Board of Directors and continues to break barriers for many Latinas in oncology.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion on the management of early-stage disease, with an eye toward applying conclusions from trials such as the ADAURA and the recent ESMO and ELCC data about perioperative chemo-immunotherapy.
Description: Host Dr. Narjust Florez and two esteemed international clinicians discuss the unique characteristics of CNS metastases in patients with non-small cell lung cancer and small cell lung cancer.Guest: Dr. Sarah Goldberg is an Associate Professor of Medicine in the section of Medical Oncology at the Yale School of Medicine. She is the Division Chief of Thoracic Oncology, the Research Director for the Center for Thoracic Cancers, and the Associate Program Director for the Medical Oncology-Hematology Fellowship Program at YaleGuest: Dr. Ernest Nadal is a medical oncologist and the director of Thoracic Tumors Section at the Catalan Institute of Oncology, an Associate Professor at the University of Barcelona, a vital member of the Spanish Lung Cancer Group and an expert in clinical trial development and interest in response and use of immune checkpoint inhibitors for the management of CNS metastases.
Continuing our series of podcasts in different world languages, this episode focuses on lung cancer research and treatment in Romanian. Host: Mihaela Aldea, MD PhD Thoracic Oncology and Precision Medicine Group Department of Medical Oncology Gustave Roussy, Villejuif, FranceGuest: Dr Cristina Ligia Cebotaru, Institute of Oncology 'Prof Dr Ion Chiricuta' Department of Radiotherapy-Medical Oncology, Cluj NapocaGuest: Dr. Paul Kubelac, Department of Medical Oncology, Institute of Oncology Cluj-Napoca-Romania
This episode of Lung Cancer Considered discusses first-line treatment options for EGFR mutant NSCLC, in Italian. Guest: Dr. Jessica Menis is a thoracic medical oncologist with expertise in early-phase trials and drug development from Azienda Ospedaliera Universitaria Integrata Verona. Jessica, welcome to the podcast.Guest: Professor Filippo de Marinis is from Istituto Europeo di Oncologia, where he is Direttore della Divisione di Oncologia Toracica, and the president of Associazione Italiana Oncologia Toracica.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recently approved bispecific T-cell engager, tarlatamab, for small cell lung cancer.Guest: Dr. Anne-Marie Dingemans is a pulmonologist and Professor of Thoracic Oncology at Erasmus Medical Center in Rotterdam, the Netherlands. Guest: Dr.Ryan Gentzler is an Associate Professor and Director of the Thoracic Oncology Clinical Research Program at the University of Virginia
In episode two summarizing important lung cancer data presented at ASCO 2024, Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu cover the phase III CROWN trial, ROS1 NSCLC with a novel ROS1 TKI, taletrectinib, the MARIPOSA trial, the PALOMA-3 trial, the WU-KONG1 data, the BEAMION-Lung1 trial, and CheckMate 77T. Guest: Dr. Clarissa Mathias is the Director of NOB/Oncoclinicas in Brazil, a member of the ASCO International Quality Steering Group and Lung Cancer Committee, and a previous IASLC Board Member.Guest: Dr. Delvys Rodriguez-Abreu is the Head of Medical Oncology at Hospital Universitario Insular de Gran Canaria and President of the Canarian Lung Cancer Foundation.
Title: ASCO 2024 Highlights Part 1 - PlenaryDescription: ASCO 2024 had so much lung cancer data, two podcast episodes are required to cover all the data presented. In this first episode, hosts Dr. Stephen Liu and Dr. Narjust Florez cover the LAURA trial, the ADUARA trial, the KRYSTAL-12 study, the phase III EVOKE-01 trial, the phase III ADRIATIC trial, and the REACH-PC trial.Guest: Dr. David Spigel is the Chief Scientific Officer at Sarah Cannon Research Institute and recipient of the IASLC Heine H. Hansen Lectureship for SCLC.Guest: Dr. Lecia Sequist is the Program Director for Cancer Early Detection & Diagnostics at Massachusetts General Cancer Center and the Landry Family Professor of Medicine in the Field of Medical Oncology at Harvard Medical School.
Host Dr. Stephen Liu moderates a discussion of lung cancer screening using low dose CT scans. Low dose CT scans have been shown to detect lung cancer earlier and significantly improve lung cancer mortality. Yet they remain underutilized and are only being used to detect certain types of lung cancer, specifically, smoking-related lung cancer.Guest: Dr. Pan-Chyr Yang is a Professor and former President of National Taiwan University College of Medicine and recipient of the IASLC Joseph W. Cullen Prevention & Early Detection Award at the 2020 WCLC.Guest: Dr. Elaine Shum is an Assistant Professor of Medicine at New York University Grossman School of Medicine and Principle Investigator of the Female Asian Nonsmoker Screening Study (FANSS), for which she received the Distinguished Young Investigator Research Award from the EGFR Resisters Summit.
May 31st is World No Tobacco Day and to observe this, Lung Cancer Considered host Dr. Narjust Florez leads a discussion on smoking cessation and how to honor the need for smoking cessation counseling without contributing to stigma. Smoking tobacco products (primarily cigarettes) is an important risk factor for the development of lung cancer and secondhand smoke is also a significant cause of lung cancer. Worldwide, smoking accounts for approximately two-thirds of lung cancer cases
May 31st is World Tobacco Day and the IASLC podcast "Lung Cancer Considered" features a leading expert on smoking cessation, Dr. Kathryn Taylor. Dr. Taylor is behavioral scientist and a Professor in the Department of Oncology at the Georgetown Lombardi Comprehensive Cancer Center in Washington DC Smoking tobacco products (primarily cigarettes) is an important risk factor for the development of lung cancer. Secondhand smoke is also a significant cause of lung cancer. Worldwide, smoking accounts for approximately 2/3 of lung cancer cases with the remaining occurring due to other causes.
In this virtual tumor board episode, host Dr. Stephen Liu leads a discussion about the management of metastatic, PD-L1 low NSCLC.Dr. Apar Ganti is a Professor of Medicine at the University of Nebraska Medical Center and the Associate Director for Clinical Research at the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska.Dr. Sze-Wai Chan from the Sandton Oncology Centre in Johannesburg, South Africa, where she is the Director and Head of Clinical Trial Research.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion about adenosquamous cell carcinoma of the lung, from diagnosis, treatment, and outcomes in this group of patients.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, other than G12C. This form of lung cancer varies by geography and incidence. KRAS mutations were once thought undruggable, but KRAS inhibitors are now available. However, not all forms of KRAS mutant lung cancers are the same and clinicians need to be aware of the difference between KRAS mutations.
In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.
As part of the IASLC’s 2024 DEI Initiative, the association is gathering member insights through an online survey and a series of virtual focus groups designed to help the organization better understand the challenges and areas for opportunity facing the global thoracic oncology profession. To take the survey, visit: https://www.iaslc.org/support-mission/iaslc-dei-initiative-global-member-surve
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marcelo Corassa. FLAURA2 was first presented at the 2023 WCLC in Singapore by Dr. Jänne.
This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Prague. Host Dr. Stephen Liu discusses the important research presented at the meeting with Dr. Jeff Bradley, Dr. Hazel O’Sullivan, and Dr. Antonio Calles.
Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive-stage disease. Unlike non-small cell lung cancer, treatments are more limited. Fortunately, the field continues to advance and there are several novel agents showing promise. In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses some of these promising therapies with Dr. Anne Chiang and Dr. Luis Paz-Ares.
This episode of Lung Cancer Considered focuses on radiopharmaceuticals-- a unique class of drugs that may have the most immediate impact in neuroendocrine tumors. Host Dr. Stephen Liu leads a discussion with three respected international clinicians about how these therapies play a role in both diagnostics and therapeutics and how they may soon be expanding.
Amivantamab Approved by FDA today, March 1!In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCLC with an EGFR exon 20 insertion, based on the phase III PAPILLON trial. These data were first shared at ESMO 2023 in Madrid with a simultaneous publication in the New England Journal of Medicine.
Today’s episode of Lung Cancer Considered is part of our special series on seminal trials in thoracic oncology, focusing on the phase I study of the PD-1 inhibitor nivolumab. Hosts Dr. Narjust Florez and Dr. Stephen Liu discuss that study with guest Dr. Julie Brahmer from Johns Hopkins University. This podcast features surprise guest interviews with several doctors who were mentored by Dr. Brahmer.
ALK fusions represent 3-5% of newly diagnosed non-small cell lung cancers but several therapeutic options do exist. Lung Cancer Considered host Dr. Narjust Florez and guests Dr. Christine Lovly from Vanderbilt University and Yvonne Diaz from Oncogene Cancer Research discuss how an ALK positive diagnosis is made and what therapies are currently available to treat it.
Lung Cancer Considered Host Dr. Stephen Liu moderates a discussion in this podcast on RET as a therapeutic target. RET fusions are a known actionable alteration and this field has blossomed very quickly. He is joined on the podcast by Dr. Oliver Gautschi from the University of Bern and Cancer Center Lucerne in Switzerland and Dr. Mihaela Aldea from Gustave Roussy in France.
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found that one-third of oncologists were unaware of evidence-based guidelines for these tests. To discuss the importance of this survey and its underlying issues, host Dr. Stephen Liu discusses some of the barriers to biomarker testing with Dr. Debora Bruno, Dr. Rami Manochakian, and Dr. Matthew Smeltzer. To take the survey, visit: https://bit.ly/BiomarkerS24
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Sally Lau leads a discussion in Cantonese about barriers to biomarker testing with Dr. Herbert Loong and Dr. Molly Li. To take the survey, visit: https://bit.ly/BiomarkerS24
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin about biomarker testing with Dr. Bo Zhu and Dr. Yuan Li. To take the survey, visit: https://bit.ly/BiomarkerS24
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for biomarker tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Alfredo Addeo discussed barriers to biomarker testing in French with Dr. Solange Peters and Dr. Maurice Perol. To take the survey, visit: https://bit.ly/BiomarkerS24
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Clarissa Mathias leads a discussion in Portuguese about biomarker testing with Dr. Vladmir Lima and Dr. Aknar Calabrich. To take the survey, visit: https://bit.ly/BiomarkerS24
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Norman Blais moderates a discussion about biomarker testing in French Canadian with Dr. Arielle Elkrief and Dr. Nicolas Marcoux. To take the survey, visit: https://bit.ly/BiomarkerS24
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To promote the survey to a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Misako Nagasaka leads a discussion in Japanese about biomarker testing with Dr.Terufumi Kato and Dr. Masahiro Tsuboi. To take the survey, visit: https://bit.ly/BiomarkerS24
Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. To discuss the importance of this survey and its underlying issues, host Dr. Narjust Florez discusses some of the barriers to biomarker testing in Spanish with Dr. Ivy Riano and Dr. Teresa Gorría. To take the survey, visit: https://bit.ly/BiomarkerS24
2024 is the 50th anniversary of the International Association for the Study of Lung Cancer and as we enter this monumental year for IASLC, we do so under a new strategic plan. To discuss what the future of IASLC looks like, hosts Dr. Stephen Liu and Dr. Narjust Florez interview four IASLC leaders to provide a glimpse into where the association is headed.
Host Dr. Sally Lau, Thoracic Medical Oncologist and Assistant Professor at the New York University Perlmutter Cancer Center, leads a discussion, in Cantonese, about biomarker testing in lung cancer and the management of EGFR mutant NSCLC.
Host Dr. Narjust Florez interviews new IASLC Chief Scientific Officer Dr. Jennifer King. In this podcast episode, Dr. King shares her perspective on how she intends to direct, guide,and support the scientific strategy of the IASLC.
Internationally respect oncologists with deep expertise in lung cancer in the Middle East discuss, in Arabic, the role of smoking in lung cancer as well as how new targeted therapies and immunotherapies assist oncologists as they treat patients with lung cancer.
In Part Two of this Lung Cancer Considered podcast on Oligometastic NSCLC, host Dr. Narjust Florez and guest Dr. Daniel Gomez discuss treatment alternatives with local therapy, focusing on radiation.
Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu host this retrospective look at the podcast, examining how the podcast started, how the team plans podcasts and what is in store for its future.
In Part 1 of a two-part podcast on Oligometastatic lung cancer and the treatment alternatives with local therapy, host Dr. Narjust Florez interviews Dr. Fatima Wilder about how local therapies, such as surgery, radiation and cryoablation impact treatment of this complex form of lung cancer.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guests discuss the importance of palliative care and psychological support for patients with lung cancer. Due to recent advances in lung cancer, we have reached a historic number of lung cancer survivors. Now more than ever, we need to ensure that patients receive appropriate support as they learn to live with lung cancer, lung cancer stigma, associated treatment side effects, and the idea of early mortality.
Internationally respect oncologists with deep expertise in lung cancer in the Middle East discuss, in Arabic, the role of smoking in lung cancer as well as how new targeted therapies and immunotherapies assist oncologists as they treat patients with lung cancer.
Lung cancer experts in Korea discuss the unique challenges they face when treating patients with lung cancer with EGFR and non-small cell lung cancer.
In this episode, host Dr. Stephen Liu leads a discussion on the current first-line treatment options for EGFR-mutant non-small cell lung cancer, including how new data from FLAURA2 and MARIPOSA may influence treatment approaches.
IASLC Lung Cancer Considered host Dr. Narjust Florez interviews two researchers presenting at the North America Conference on Lung Cancer:Dr. Carolyn Presley is an Associate Professor in the Division of Medical Oncology/Department of Internal Medicine at The Ohio State University, Comprehensive Cancer Center and The James Cancer Hospital/Solove Research Institute.Alexandra Potter is co-founder and President of the American Lung Cancer Screening Initiative.
Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-cohort TRIDENT-1 trial.
Sexual health of patients with lung cancer is poorly understood, highly prevalent, and not frequently discussed. However, sexual concerns are common in people with lung cancer, with many receiving very little information compared to patients diagnosed with cancer that affects a sexual or reproductive organ. In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion with two national experts on how patients with lung cancer can maintain their sexual health during and after lung cancer diagnosis and treatments.
Host Dr. Narjust Florez leads a discussion about the data from the KEYNOTE 671 trial, presented at ASCO 2023 and ESMO 2023, that led to the first approval of the combination of pembrolizumab plus chemotherapy in the neoadjuvant and adjuvant setting.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the role of neoadjuvant therapy for stage III NSCLC using a virtual tumor board format. This area has become increasingly complex of late, as we have seen several large studies report encouraging results with peri-operative immunotherapy and targeted therapy.
This episode of Lung Cancer Considered covers the current treatment and research landscape in The Netherlands. The episode is recorded in Dutch and is hosted by Dr. Lizza Hendriks from the Maastricht University Medical Center. Guests are Anne Marie Dingemans from Erasmus MC, Rotterdam, The Netherlands and Anthonie Vd Wekken from the University Medical Centre Groningen.
Lung Cancer Considered host Dr. Narjust Florez leads an informed discussion on the AEGEAN Trial, which explored neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resected NSCLC.
Title:Lung Cancer Care in India: Approaching a Lung Cancer Diagnosis (Hindi language podcast)The podcast is recorded in Hindi and covers a range of crucial lung cancer topics, including the emergence of adenocarcinoma as the dominant histological type, delays in diagnosis related to misdiagnosis as tuberculosis, and the importance of accurate staging and biomarker testing.
In this podcast, host Dr. Stephen Liu moderates a discussion a recent FDA approval and a specific molecular subtype of NSCLC. On October 11, 2023, the US FDA granted approval to encorafenib and binimetinib for advanced NSCLC harboring a BRAF V600E mutation based on the phase II PHAROS trial.
Part 2 of our podcast coverage on ESMO 2023 includes an in-depth interview with Dr. Jarushka Naidoo on early-stage NSCLC, including updates from CheckMate816, Keynote 671 overall survival results, and Checkmate77T, first perceptions about the data, remaining unanswered questions and how to incorporate to our clinical practice. Further, we discussed exciting data in the 2nd line setting for Small-Cell Lung Cancer and a new potential therapeutic option for thymic carcinoma. Tune in for this thought-provoking, data-driven, and practical episode of Lung Cancer Considered.
In the first part of two podcasts covering recent data presented at the European Society of Medical Oncology Congress 2023, host Dr. Stephen Liu summarizes the most compelling research on metastatic non small cell lung cancer from the meeting with Dr. Zosia Piotrowska and Dr. Noemi Reguart, discussing several impactful studies including MARIPOSA, MARIPOSA-2, LIBRETTO-431, TROPION-Lung01 and more as well as reviewing the importance of CNS efficacy and the evolving role of antibody drug conjugates (ADCs).
Today’s episode of Lung Cancer Considered is recorded entirely in Japanese and focuses on EGFR mutated lung cancer.
In this special episode of Lung Cancer Considered recorded in Hungarian, lung cancer experts in Hungary and the United States discuss challenges and emerging strategies to treat lung cancer in Hungary.
Mesothelioma is a particularly challenging cancer to treat and there had been relatively few updates in its management until the recent integration of immunotherapy into treatment guidelines. To discuss current strategies to treat Mesothelioma, Dr. Stephen Liu leads an informed discussion with two international Mesothelioma experts.
In this episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu preview the 2023 North America Conference on Lung Cancer, scheduled for December in Chicago, December 1 - 3. The deadline for abstract submission is October 26th. Visit https://www.iaslc.org/2023-north-america-conference-lung-cancer to learn more.
Lung Cancer Considered Hosts Dr. Narjust Florez and Dr. Stephen Liu wrap up WCLC 2023 in Singapore, discussing the meeting's most impactful research, including MARS2, FLAURA2, TRIDENT, HERTHENA, and TROPION.
Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu recap three important sessions from Tuesday, September 12th at the IASLC WCLC 2023: Advocates Unite to Increase Lung Cancer Research Funding An update on the AEGEAN Trial--Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable Long-term Outcomes by Radiation Technique for Locally Advanced Non-Small Lung Cancer: A Secondary Analysis of NRG Oncology-RTOG 0617 at 5-years
MARS 2 in Spanish--Monday WCLC Highlights In this Spanish-language podcast, Lung Cancer Considered Host Dr. Narjust Florez enlists two colleagues to discuss the MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma.
Guests: Dra. Rosanna Ruiz, Oncologo clínico Institutio nacional de enfermedades neoplásicas, Lima, Peru
Dr. Ricardo Terra, Cirujano toracico Professor, the cirugia toracica en la universidad de Sao Paolo, Brazil
Monday at WCLC 2023 features the Presidential Symposium. In this special WCLC 2023 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu talk with Dr. Eric Lim about MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Dr. Paula Ugalde, discussant for MARS 2, provides her unique overview and perspective on research presented today. The hosts also talk with Dr. P.C. Yang about the new results presented in the TALENT study of lung cancer screening in Taiwan. Patient advocate Emi Bossio adds her unique perspective. Additionally, Dr. Pasi Janne summarizes his presidential abstract: Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2) and is joined in a discussion with Emi Bossio, a patient with EGFR lung cancer.
Professor Eric Lim is a Consultant Thoracic Surgeon at the Royal Brompton Hospital and Professor of Thoracic Surgery at the National Heart and Lung Institute of Imperial College London.
Pan-Chyr Yang, MD, PhD--National Taiwan University College of Medicine and National Taiwan University Hospital, Institute of Biomedical Sciences, Genomics Research Center, Academia Sinica, Taiwan.
Paula Ugalde – Dr. Paula Ugalde Figueroa, Thoacic Surgeon, Brigham and Women's Hospital
Pasi Jänne is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute
Sunday highlights from WCLC 2023 include hosts Dr. Narjust Florez and Dr. Stephen Liu discussing two-year data from KRYSTAL-1 with Dr. Shirish Gadgeel; a discussion of the IASLC Language Guide and patient-centered language with noted lung cancer patient advocate Jill Feldman; and six-year follow-up data from CheckMate 227 with Dr. Solange Peters.Panelists:Shirish Gadgeel, MD is the Associate Director of Henry Ford Cancer Institute and the Chief of Division of Hematology/Oncology at Henry Ford Health. He is also Professor of Internal Medicine at Michigan State University. Jill Feldman, Lung Cancer Patient and Advocate, Twitter: Solange Peters, MD, PhD Chair and Professor, Medical Oncology, Full Professor, University Hospital of Lausanne, Lausanne, Switzerland.
From lung cancer in women to gender equity in the healthcare workforce, IASLC is privileged to host HRH Princess Dina Mired of Jordan at the 2023 World Conference on Lung Cancer. In this special episode of Lung Cancer Considered, host Dr. Narjust Florez, IASLC President Dr. Heather Wakelee, and WCLC 2023 co-chair Dr. Fiona Hegi-Johnson discuss global advocacy through a gender equity lens, lessons learned from the field, and how HRH Dina Mired’s experience as the mother of a cancer survivor has impacted her work and initiatives globally.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses targeted therapies, what they are, and how they have changed our approach to treating not just lung cancer, but cancers in general.Guest: Dr. Vivek SubbiahDr. Subbiah is the Chief of Early Phase Drug Development for Sarah Cannon Research Institute. He was previously the Executive Director of Medical Oncology Research for the MD Anderson Cancer Network, where he played a pivotal role in the development and ultimate approval for several agents that we consider essential in the lung cancer world.
In this epidose of Lung Cancer Considered, Dr. Narjust Florez leads a discussion on the journey to an oncology fellowship.
Medical training is long, full of sacrifices and student debt for many. For our listeners, after graduating from pre-med or undergraduate studies future physicians need to complete 4 years of medical school, followed by 3 years of internal medicine residency or 5 years of surgery or radiation oncology residency. For internal medicine residents they need to complete 3 to 4 additional years of hematology and oncology fellowship.
Today we will be discussing recommendations for a smooth search, transition, and completion of an oncology fellowship.
Guests: Dr. Christine Garcia, thoracic medical oncologist and fellowship program director at Weill Cornell Medicine in NYC.
Dr. Regina Barragan-Carrillo, who completed her medical oncology fellowship in the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City and is currently a research fellow at City of Hope.
Dr. Jennifer Marks, chief oncology fellow at Georgetown University with a focus on thoracic oncology.
Artificial intelligence is one of the most significant trends in most parts of society. Increasingly, oncologists and lung cancer researchers are including AI in research and patient care. In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of this compelling technology, focusing on its promise and limitations. Guests: Dr. Sanja Dacic, MD, PhD, MSc, an internationally renowned and highly accomplished leader in anatomic pathology and the Vice Chair and Director of Anatomic Pathology in the Department of Pathology at Yale School of Medicine. She currently serves as president of the Pulmonary Pathology Society. Dr. Fabio Ynoe de Moraes, MD, PhD, MBA - an Associate Professor and clinical investigator in radiation and global oncology at the Queen’s University and Kingston Health Sciences Centre, Kingston, ON, Canada. Dr Moraes has more than one hundred published peer-reviewed articles (i.e., NEJM, Lancet Oncology, Nature Medicine, Nature Biotechnology) and holds a PhD in Health Sciences (Oncology) and post graduate degree in artificial intelligence and machine learning and is one of the upcoming IASLC 2024 WCLC Chairs.
Greece ranks third in mortality in Europe from lung cancer, surpassed by Hungary and Serbia. In this episode of Lung Cancer Considered, host Dr. Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at the Henry Dunant Hospital in Athens, Greece, leads a discussion on the efforts from the Hellenic scientific community to implement smoking cessation strategies, screening programs, multidisciplinary approach and personalized treatment approaches of the Greek patient with lung cancer.
Guests include: Helena Linardou is a Medical Oncologist, is Director of the 4th Oncology Dept and the Comprehensive Clinical Trials Center of Metropolitan Hospital in Athens, Greece. She completed a research Fellowship in Oncology and obtained her PhD Degree from Imperial College, University of London, UK
Konstantinos Leventakos is a Medical Oncologist, assistant Professor at the Mayo Clinic in Rochester, USA, with a focus on thoracic malignancies, personalized medicine and immunotherapy.
This episode of Lung Cancer Considered previews the upcoming IASLC Hot Topic in Basic and Translational Science Meeting on Resistance to Immunotherapy in NSCLC. Joining host Dr. Stephen Liu are: Guests: Dr. Joachim Aerts, Professor of Pulmonary Oncology at Erasmus University Rotterdam and Head of Pulmonary Medicine at Erasmus MC in the Netherlands. Dr. Kellie Smith, Associate Professor of Oncology at Johns Hopkins University. Dr. Roberto Ferrara, Medical Oncologist and Immunologist, from Istituto Nazionale dei Tumori di Milano in Milan, Italy.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the management of small-cell lung cancer using a virtual tumor board format. SCLC is an aggressive subtype of lung cancer and for patients with advanced, or extensive-stage disease, the current first-line standard of care is chemo-immunotherapy. In the US and in Europe, the approved options are platinum and etoposide with a PDL1 inhibitor: either atezolizumab based on the IMpower 133 trial or durvalumab based on the CASPIAN trial.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discuss some of the highlights from iMig 2023 – the meeting of the International Mesothelioma Interest Group, an IASLC-endorsed meeting held in late June 2023 in Lille, France.
Guests: Dr. Arnaud Scherpereel, the iMig President and 2023 Conference Chair, currently Professor of Pulmonary and Thoracic Oncology at the University Hospital of Lille.
Dr. Jan van Meerbeeck, Professor of Thoracic Oncology at both Ghent and Antwerp University and Chair of Pulmonology at Antwerp University Hospital. He was also co-Chair of the 2023 iMig meeting
This episode of Lung Cancer Considered examines the treatment of EGFR-positive lung cancer in Brazil from early-stage disease to metastatic lung cancer.
Podcast guests: Dr. Juliana Ominelli, a Brazilian practicing medical oncologist in Rio de Janeiro, Brazil with experience treating EGFR Lung Cancer. She practices at the Brazilian National Cancer Institute –Oncologia DASA.
Dr. Victor Marcondes, thoracic medical oncologist from Rio de Janeiro, Brazil who practices at Oncomed Oncologia and has led several trials in the region focusing on EGFR-positive NSCLC,
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion with two global experts about the current and future roles of liquid biopsy and its use for the treatment of lung cancer.
In this episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu lead a discussion on the recently completed ASCO 2023 meeting that included presentation of the new overall survival data from the ADAURA trial as well as the New England Journal of Medicine publication on data from KEYNOTE 671.
WCLC 2023 is a global, multi-disciplinary meeting designed for physicians, nurses, clinicians, researchers, scientists, survivors and advocates. This year, the meeting rotates to Singapore and Lung Cancer Considered Hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by the meeting's three co-chairs for a wide-ranging interview about how attendees can make the most out of their experience during IASLC's flagship annual conference.
LCC in Polish: Overcoming Barriers to Lung Cancer Therapy in Poland This special Polish-language episode of Lung Cancer Considered focuses on the unique challenges facing clinicians, researchers, and patients in Poland. The podcast also focuses on how physicians help patients overcome barriers to treating lung cancer. Host: Dr Anna Wrona, Department of Oncology and Radiotherapy, Medical University of Gdansk Guests: Professor Rafał Dziadziuszko, M.D., Ph.D., Head, Department of Oncology & Radiotherapy and Early Phase Clinical Trials Centre at the Medical University of Gdańsk Professor Witold Rzyman, M.D., Ph.D. Head, Department of Thoracic Surgery at the Medical University of Gdańsk
In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses ROS+1 Fusions in NSCLC, including diagnosis, treatment and new exciting research coming down the pipeline. Her guests are:Dr. Lorenza Landi, Director of Clinical Trials Unit: Phase 1 and Precision Medicine at the National Cancer Institute Regina Elena in Rome. Dr. Landi has extensive experience and is interested in targeted therapy in lung cancer with a focus on ALK, HER-2/EGFR positive and ROS+1 lung cancer.Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology, at Henry Ford Cancer Institute in Detroit, Mich. Dr. Gadgeel is also part of the Lung Cancer steering committee for the Southwest Oncology Group and he is the Associate Editor of Clinical Lung Cancer and a reviewer for many journals.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on EGFR NSCLC and transformation to small cell lung cancer, a relatively new finding since the introduction of targeted therapy.
Lung Cancer Considered hosts Dr. Narjust Flores and Dr. Stephen Liu talk with Dr. Roy Herbst about the ADAURA Trial. ADAURA introduced targeted therapy in the adjuvant setting for early-stage EGFR positive NSCLC. While we have seen targeted therapy in this space ADAURA showed DFS rates never seen before and changed the treatment of early-stage lung cancer.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez interviews Dr. Emily Stone, the new editor of JTO Clinical and Research Reports. The podcast will focus on her article “Building on a Legacy”.
Host Dr. Alfredo Addeo, Senior Oncologist, Geneva University Hospital, in Geneva, Switzerland moderates a special French-language episode of Lung Cancer Considered focusing on managing locally advanced NSCLC. The guests for this special podcast are Dr. Cecile Le Pechoux, Radiation Oncologist at Department of Radiation Oncology Unit of Thoracic Oncology, Soft Tissue Sarcomas and Mesenchymal Tumour, and Dr. Jonathan Spicer, Associate Professor, Division of Thoracic Surgery. Director, McGill Thoracic Oncology Network, McGill University, Montreal General Hospital.
This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Copenhagen. Host Dr. Stephen Liu, Dr. Heather Wakelee and Dr. Paul Van Schil discuss the important research presented at the meeting.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a new Virtual Tumor Board on EGFR mutant NSCLC and acquired resistance. Dr. Liu is joined by two thoracic medical oncologists who are both global experts in targeted therapy.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a conversation about small cell lung cancer and previews the upcoming IASLC 2023 Hot Topic Meeting: Small Cell Lung Cancer in April which is focused on both preclinical and clinical advances in small cell lung cancer research. Joining the conversation are Dr. Alvaro Quintanal-Villalonga from the Rudin Lab at Memorial Sloan Kettering Cancer Center in New York, and Dr. Kate Sutherland from the Walter and Eliza Hall Institute of Medical Research in Australia.
In this episode of Lung Cancer Considered, recorded at the 2023 Targeted Therapies of Lung Cancer meeting, host Dr. Narjust Florez moderates a conversation about the use of consolidated radiation in early-stage small cell lung cancer. Joining the debate are Dr. Lawrence Einhorn from the Indiana University School of Medicine and Dr. Charles Simone from Memorial Sloan Kettering.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a recap of the recent IASLC meeting, Targeted Therapies for Lung Cancer, or TTLC23 --a member-favorite, a relatively smaller meeting known for its fast pace and its breadth of content. Guests include, the two co-chairs of the meeting:Dr. Charu Aggarwal, thoracic medical oncologist at the Hospital of the University of Pennsylvania and the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania. Dr. Joel Neal, thoracic medical oncologist and Associate Professor at Stanford University where he is also the Medical Director for the Cancer Clinical Trials Office.
In this Virtual Tumor Board episode of Lung Cancer Considered, host Dr. Stephen Liu and his guests discuss the dynamic topic of managing resectable stage III NSCLC. Joining him are: Dr. Isabelle Schmitt-Opitz, Professor of Thoracic Surgery and Director of the Department of Thoracic Surgery at University Hospital of Zurich, Chair of the Lung Cancer Center of Zurich, and the President of the European Society of Thoracic Surgery. She received the IASLC Robert J Ginsberg Lectureship Award for Surgery at the 2022 World Conference on Lung Cancer. Dr. Jonathan Spicer, Medical Director of the Thoracic Oncology Program at McGill University in Montreal where he is the Advanced Thoracic and Upper GI Surgical Oncology Fellowship Program Director. He is also a co-author of the CheckMate 816 study. Dr. Tina Cascone, Assistant Professor and Thoracic Medical Oncologist at the University of Texas MD Anderson Cancer Center and Principal Investigator of the neoadjuvant NEOSTAR study.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on a specific subset of lung cancer: EGFR exon 20 insertion NSCLC. Joining the podcast are distinguished panel of clinicians and lung cancer advocates: Dr. Rosario Garcia Campelo, the Head of Medical Oncology and the Thoracic Tumor Unit Chair at the University Hospital A Coruna, Spain. Marcia Horn, executive director of the Exon 20 Group and CEO of ICAN, the International Cancer Advocacy Network. Yonsei University College of Medicine, Professor Byoung-Chul Cho, Director of the Lung Cancer Center at Yonsei Cancer Hospital in Seoul, South Korea.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion about NSCLC with RET rearrangements, including diagnosis, treatment, and new exciting research coming down the pipeline. Podcast guests are: Dr. Justin Gainor, the Director of the Center for Thoracic Cancers at the Massachusetts General Hospital (MGH), Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies, and Co-Leader of the SU2C Lung Cancer Dream Team. His major research interests have focused on targeted therapy and immunotherapy. Dr. Lizza Hendricks, Assistant Professor at research institute GROW, School for Oncology and Developmental Biology of Maastricht University in the Netherlands. Her focus area is thoracic oncology, in particular prevention and optimal treatment of brain metastases in lung cancer and targeted therapy. Since 2019, Dr Hendriks has coordinated the clinical lung cancer research of the lung diseases department in Maastricht.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a conversation on KRAS G12C mutation. Joining the podcast are Dr. Melissa Johnson, the Program Director of Lung Cancer Research at the Sarah Cannon Research Institute and Dr. Ferdinandos Skoulidis, an Associate Professor at the University of Texas MD Anderson Cancer Center.
The Latin American Conference on Lung Cancer, held in Uruguay, wrapped up in late January. To provide a summary of key findings from the meeting, Lung Cancer Considered host Dr. Narjust Florez interviewed two prominent oncologists from South America: Dr. Clarissa Mathias, Dr. Mathias is a medical oncologist and director of NOB/Oncoclinicas in Brazil. She is a member of the ASCO International Quality Steering Group and Lung cancer committee. Dr. Mathias served on the IASLC board and has led many efforts in thoracic oncology in Brazil and recently hosted an episode of Lung Cancer Considered in Portuguese. Dr. Carlos Barrios, born in Uruguay but practicing oncologist in Brazil. Dr. Barrios is Director and Principal Investigator of the Oncology Research Center at Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul since 1996, where he has participated in more than 300 clinical research trials during the past 15 years. He is Director of Clinical Research and Oncologist of the Oncoclínicas Group in Porto Alegre. He is Adjunct Assistant Professor of the William Harrington Latin American Program of the University of Miami School of Medicine.
On January 26, 2023, the US FDA granted approval of pembrolizumab, an anti-PD-1 antibody, as an adjuvant therapy for patients with resected NSCLC. In this episode of Lung Cancer Considered host Dr. Stephen Liu leads a discussion on this approval with two thoracic medical oncologists with extensive expertise in this space: Dr. Jamie Chaft, an Associate Attending at Memorial Sloan Kettering Cancer Center, where she is the Director of Early Stage Lung Cancer Research, chair of the adjuvant nivolumab trial within the ALCHEMIST program and heavily involved in perioperative systemic therapy studies. Dr. Mary O’Brien, Professor and Consultant Medical Oncologist at the Royal Marsden in Surrey, Head of the Lung Unit, and chair of the EORTC Lung Cancer Group. She was one of the investigators on the KEYNOTE 091 trial which provided key data that lead to this approval.
In this special episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez discuss the seminal IPASS trial with its principal investigator, Dr. Tony Mok. IPASS was a randomized phase III trial that compared the EGFR TKI gefitinib to carboplatin plus paclitaxel and showed, for the first time, that in a selected population, targeted therapy was superior to chemotherapy. The initial results were published in the New England Journal of Medicine in 2009 and helped usher in the era of precision oncology. Dr. Tony Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. He cofounded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group.
In a special episode of Lung Cancer Considered focusing on lung cancer in Brazil, host Dr. Clarissa Mathias, medical oncologist at Oncoclinicas Bahia and Hospital Santa Izabel, is joined by Dr. Ticiana Leal, associate professor, Department of Hematology & Oncology and director of Thoracic Medical Oncology, Winship Cancer Institute, Emory University and Dr. Carlos Gil Ferreira, president of Instituto Oncoclinicas and chief medical officer – Oncoclínicas.
Host Dr. Narjust Florez engages with three leading lung cancer patient advocates on the importance of patient advocacy groups, how these were formed, challenges when managing large patient advocacy groups and the future of patient advocacy in lung cancer. Janet Freeman-Daily is a cancer patient research advocate and activist who translates the experience and science of cancer for others. She was diagnosed with advanced lung cancer in 2011 and metastatic ROS1+ lung cancer in 2012. She collaborates, writes, and speaks with cancer organizations both internationally and within the USA, and blogs at Gray Connections. Seamus Cotter is from Ireland and was diagnosed with stage IV NSCLC lung cancer in June 2016 and has shared his experiences with immunotherapy on many global platforms. Since his diagnosis, Seamus has been involved in drug development and the improvement of clinical trials in lung cancer. He is deeply involved in the Irish Lung Cancer Community and is also a Patient Consultant on the lung group in Cancer Trials Ireland. Terri Conneran is one of the founders of the non-profit group “KRAS Kickers.” She was diagnosed with stage IIIa KRAS + lung cancer and has experienced separate recurrences and has persevered through multiple treatments and has dedicated her time to patient advocacy. Terri has shared her story on national and international platforms and created a community beyond lung cancer for all patients with KRAS-driven cancers.
Radon exposure is a known risk factor for lung cancer yet it does not garner as much attention as other risk factors. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses radon, its impact on lung cancer diagnosis, new research covering radon and strategies to improve our patients and the general population's exposure to this radioactive gas. Her guest is Dr. Hina Khan, thoracic medical oncologist at the Lifespan Cancer Center and an assistant professor at The Warren Alpert Medical School of Brown University. Dr. Khan has studied the effect of radon in lung cancer and its genomic profile.
Radiologists play central roles in the detection of lung cancer, in assessing response to therapy and relapse of disease and increasingly, interventional radiologists are involved with tissue sampling and lung cancer treatment. In this episode of Lung Cancer Considered, host Dr. Stephen Liu interviews two noted radiologists--Dr. Carole Ridge and Dr. Florian Fintelmann.Dr. Ridge is a consultant radiologist at Royal Brompton Hospital and a Senior Clinical Research Fellow at Imperial College London. Her research was awarded the Royal Academy of Medicine in Ireland medal in 2018.Dr. Florian Fintelmann is an Associate Professor at Harvard Medical School and a thoracic radiologist at Massachusetts General Hospital. He also leads the Thoracic Imaging Percutaneous Thermal Ablation program at the MGH.
This week, the FDA granted accelerated approval to Adagrasib to treat advanced NSCLC with a KRAS G12C mutation after at least one prior line of systemic therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu and two guests discuss the approval and what impact it will have on patients and clinicians. Joining the podcast are Dr. Joshua Sabari (@JSabari), assistant professor of Medicine and Thoracic Oncologist at NYU Perlmutter Cancer Center in New York City, and Dr. Sheena Bhalla (@SheenaBhallaMD), assistant professor of Medicine and Thoracic Oncologist at UT Southwestern Medical Center in Dallas.
In this special edition of Lung Cancer Considered, three oncologists and lung cancer experts explore lung cancer in Israel, spoken in Hebrew.Host Dr. Alona Zer, Head of the Department of Medical Oncology at the Rambam Health Care Campus, Haifa, Israel welcomes guests Dr. Jair Bar, Deputy Director, Institute of Oncology at Chaim Sheba Medical Center and Associate Professor of Oncology, School of Medicine at Tel Aviv University and Dr. Nir Peled, Head, the Cancer Institute at Shaare Zedek Medical Center and Full Professor, Internal Medicine & Medical Oncology, Faculty of Health Sciences at Ben-Gurion University of the Negev, Beer Sheva, Israel.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu and invited guests to discuss the IASLC Asian Conference on Lung Cancer (ACLC) held in Japan and the ESMO Asia meeting held in Singapore. Guests include Dr. James Yang, director and Professor of the Graduate Institute of Oncology at the National Taiwan University and the director of the Department of Oncology at the National Taiwan University Hospital, Dr. Thanyanan Baisamut, consultant in the Division of Medical Oncology at Ramathibodi Hospital and Mahidol University in Thailand, and Dr. Takashi Setothor, thoracic medical oncologist from the National Kyushu Cancer Center in Fukuoka, Japan.
In this special edition of Lung Cancer Considered, three oncologists and lung cancer experts explore lung cancer in the Middle East (North Africa), spoken in Arabic.Host Dr. Nagla Karim, MD, PHD, Director of the Phase I Programat the Inova Schar Cancer Institute welcomes guests Dr. Abdelrahman Mohamed, MD, Head of Thoracic Surgery, NCI at Cairo University and Dr. Houssein Abdul Sater, MD, Physician Scientist, Immuno-Oncology and Regional Research Director, Cancer Institute at Cleveland Clinic Florida.
This episode of Lung Cancer Considered covers a subset of patients with non-small cell lung cancer with lung cancer -- MET exon 14 skipping mutations. MET exon 14 skipping mutations occur in approximately 3 to 4% of patients with NSCLC, typically in the absence of other driver mutations. Host Dr. Narjust Florez will discuss the unique clinical issues surrounding MET exon with Dr. Ross Camidge, Director of the Clinical and Research Thoracic Program at the University of Colorado and Dr. Noemi Reguart, Clinical Professor at the University of Barcelona.
This episode of Lung Cancer Considered is part of our series on FDA approvals of new lung cancer therapies. Today, host Dr. Stephen Liu discusses the EMPOWER-Lung 3 regimen of the PD-1 inhibitor cemiplimab with first-line platinum doublet chemotherapy for advanced NSCLC. This regimen was approved by the FDA on November 8, 2022. His guests are Dr. Jordi Remon, a thoracic medical oncologist who had previously practiced at Hospital de Mataro in Barcelona. He is now part of the esteemed thoracic unit at Gustave Roussy in Paris and the secretary of the Lung Cancer Group of EORTC. Joining Dr. Remon is Dr. Isabel Preeshagul, a thoracic medical oncologist and Assistant Attending with Memorial Sloan Kettering. She is also the chair of the Education and Engagement Committee of the Lung Cancer Research Foundation.
Dr. Narjust Florez discusses the POSEIDON trial with guest Dr. Tejas Patil, assistant professor at Thoracic Oncology Research Initiative, University of Colorado Cancer Center. This Phase III study led to the recent FDA approval of Tremelimumab in combination with Durvalumab and chemotherapy as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC).
There has been a steady stream of research presented that ties air pollution to an increased risk for lung cancer. To discuss this trend, Lung Cancer Considered host Dr. Narjust Florez interviews Dr. Roselle De Guzman, who is a medical oncologist and professor at the Manila Central University in the Philippines and the Chair of ASCO Asia Pacific Regional Council. Joining her is Dr. Christine D. Berg, former Chief, Early Detection Research Group, Division of Cancer Prevention, at the National Cancer Institute.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu, Director of Thoracic Oncology at Georgetown University, leads a discussion about the management of stage III NSCLC. Joining him are pulmonologist Dr. Martin Reck, Head of the Department of Thoracic Oncology and the Head of the Clinical Trials Department at the Lung Clinic Grosshansdorf and thoracic surgeon Dr. Paula Antonia Ugalde Figueroa, an Associate Surgeon in the Division of Thoracic Surgery at Brigham and Women’s Hospital in Boston, MA. Dr. Reck has led many of the oncology trials that have defined the standard of care for lung cancer including KEYNOTE-024 and more recent efforts in stage III NSCLC like KEYNOTE-799. Dr. Ugalde has been a pioneer in minimally invasive surgery from her time as director of Thoracic Oncology research at Laval University in Quebec to her current position at the Dana Farber Cancer Institute. She is currently a member of the Board of Directors of IASLC.
At the time it was published in the New England Journal of Medicine in 2002, ECOG 1594 was the first study to compare whether any of the three chemotherapy regimens used at the time was superior to cisplatin and paclitaxel in patients with advanced non–small-cell lung cancer. In this episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez interview the ECOG 1594 clinical trial investigators (Dr. Frances Shepherd, Dr. Alan Sandler, Dr. Chandra Belani, Dr. Corey Langer and Dr. Joan Schiller) to learn just how important, and controversial, this study was.
Lung cancer research is often centered at large, urban academic medical centers. But what research and treatment options are available for those patients with lung cancer who live in rural areas? In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses the state of rural lung cancer care and research with Dr. Debora Bruno, a thoracic medical oncologist at Case Western in Cleveland. Dr. Bruno worked in rural Nebraska for three years after the completion of her fellowship where she was able to help establish a multi-disciplinary clinic for patients with lung cancer. Also participating in the podcast is Dr. Gabrielle Rocque, associate professor of medicine at the O’Neal Comprehensive Cancer Center at the University of Alabama. Dr. Rocque has a strong interest in the interface between community oncology practices and academia.
In this special edition of Lung Cancer Considered, three esteemed oncologists and lung cancer experts explore the issues facing the medical profession in China.Host Dr. Chunxia Su, Professor of Oncology at Tongji University and Deputy Director of Medical Oncology at Shanghai Pulmonary Hospital, welcomes guests Prof. Shun Lu, Director of the Chinese Lung Cancer Association, Board Member of the Chinese Society of Clinical Oncology, and Director of the Shanghai Lung Cancer Center; and Prof. Caicun Zhou, Chief Physician and Director of Medical Oncology at Tongji University in Shanghai Pulmonary Hospital and current member of the IASLC Board of Directors.
In keeping with its mission to cover lung cancer from a global perspective, this episode of Lung Cancer Considered focuses on lung cancer in Japan. Host Dr. Misako Nagasaka, a Thoracic Medical Oncologist from the University of California Irvine leads a Japanese-language discussion about lung cancer in Japan with respected oncologists Dr. Tetsuya Mitsudomi and Dr. Takashi Seto. Dr. Seto is a Thoracic Medical Oncologist from the National Kyushu Cancer Center in Fukuoka, Japan and Dr. Tetsuya Mitsudomi is a Professor in the Division of Thoracic Surgery at Kindai University in Osaka-Sayama, Japan. He is also the immediate past IASLC president.
Over the past few years, the use of liquid biopsy has improved the ability to detect biomarkers for non-small cell lung cancer. In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the current state of liquid biopsies with Dr. David Gandara, Professor of Medicine and Director of Thoracic Oncology at the University of California, Davis; Dr. Charu Aggarwal, the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania; and Dr. Christian Rolfo, Professor of Medicine at Mount Sinai in New York City and the Associate Director for Clinical Research in the Center for Thoracic Oncology at the Tisch Cancer Institute.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks about the critical role interventional pulmonologists play on the cancer care team. Joining the discussion are Dr. Daniel Sterman, the Thomas and Suzanne Murphy Professor of Pulmonary and Critical Care Medicine at the New York University Grossman School of Medicine and Dr. Rebecca Krochmal, Assistant Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at the Georgetown University School of Medicine.
Did you miss ESMO this year? Listen to Lung Cancer Considered host and thoracic oncologist Dr. Narjust Florez discuss the key highlights involving science and notable abstracts at the meeting with Dr. Joshua Reuss, Thoracic Medical Oncologist and Assistant Professor of Medicine at Georgetown and Dr. Giannis Mountzios, Director of the Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center in Athens, Greece.
The role of the pathologist in lung cancer treatment has dramatically evolved as our understanding of lung cancer biology has advanced. Lung Cancer Considered host Dr. Stephen Liu discusses that evolution with renowned lung cancer pathologists Dr. Dara Aisner from the University of Colorado and Dr. Ignacio Wistuba from MD Anderson Cancer Center. Dr. Wistuba is a Professor in the Department of Thoracic and Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston. He is the Head of the Division of Pathology and Lab Medicine and an expert in translational pathology. Dr. Aisner is an Associate Professor in the Department of Pathology at the University of Colorado in Aurora, CO. She has expertise in Anatomic as well as Molecular Genetic Pathology and is the Medical Director of the Colorado Molecular Correlates Laboratory.
Lung Cancer Considered Host Dr. Stephen Liu leads a recap of the recently completed IASLC 2022 North America Conference on Lung Cancer featuring guests Dr. Jessica Donington, Professor and Chief Thoracic Surgery University of Chicago; Dr.Jyoti Patel, Thoracic Medical Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University and Dr. Shruti Patel, Oncology Fellow at Stanford School of Medicine.
Career transitions are normal in academic oncology, oncology practice, and industry and today's oncologists go through a number of 'job' interviews during their post-graduate life and early career. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses how to find or transition to that new job in thoracic oncology. Joining the discussion are three lung cancer researchers:
Dr. Mark Awad, clinical director of the Thoracic Oncology Group at Dana Farber Cancer Institute, assistant professor of Medicine at Harvard Medical School and a leading researcher in KRAS-mutant NSCLC.
Dr. Ana Velazquez, instructor of medicine and thoracic medical oncologist at UCSF and a postdoctoral fellow at the National Clinical Scholars Program. Dr. Velazquez is completing her training and searching for her faculty position.
Dr. Jyoti Patel, associate vice for clinical research, a thoracic medical oncologist, and professor of medicine at Northwestern University in Chicago. Dr. Patel is a leader in thoracic oncology, focusing her efforts on the development and evaluation of novel molecular markers and therapeutics for patients with non-small cell lung cancer.
Treatment for malignant pleural mesothelioma has undergone dramatic shifts in the past few years. To discuss these changes and the research behind them, Lung Cancer Considered Host Dr. Stephen Liu welcomes Dr. Sanjay Popat and Dr. Melina Marmarelis. Dr. Popat is a Consultant Thoracic Medical Oncologist at The Royal Marsden and Professor of Thoracic Oncology at the Institute of Cancer Research, in London, England, and Chair of the British Thoracic Oncology Group. He is also on the Board of Directors for the Mesothelioma Applied Research Foundation. Dr. Marmarelis is an Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and the Medical Director of the Penn Mesothelioma and Pleural Program.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the management of metastatic, PDL1 negative NSCLC. He is joined by Dr. Hossein Borghaei and Dr. Reyes Bernabe Caro.
Dr. Borghaei is a professor and Chief of Thoracic Oncology at Fox Chase Cancer Center in Philadelphia. He was the lead author for CheckMate 057, was involved in many of the landmark immunotherapy trials, and is the national PI for the ongoing INSIGNA trial. Dr. Reyes Bernabe Caro is the Section Chief of Medical Oncology and Head of the Thoracic Tumor Unite at the Hospital Universitario Virgen Rocio in Seville, Spain. She also has extensive experience in immunotherapy combinations and is an author on the NADIM and CheckMate 227 studies.
On the heels of accelerated approval by the US FDA, Dr. Stephen Liu discusses trastuzumab-deruxtecan (T-DXd) with medical oncologists and clinical investigators, Dr. Lyudmila Bazhenova, from the University of California, San Diego, and Dr. Julian Mazieres, from Toulouse University Hospital. T-DXd is an antibody-drug conjugate now approved for the treatment of HER2-mutant NSCLC, and in this episode, its design, efficacy, and safety are reviewed.
It’s a wrap! Catch up on key highlights of the IASLC 2022 World Conference on Lung Cancer with Dr. Narjust Florez and Dr. Stephen Liu as they discuss the science, social engagement and notable abstracts with Dr. Ben Levy.
We’ve approached a remarkable close to the last day of the IASLC 2022 World Conference on Lung Cancer in Vienna, Austria. Lung Cancer Considered hosts Dr. Stephen Liu and Dr. Narjust Florez interview Dr. Belinda King Kallimanis, Dr. Charles Rudin and Dr. Solange Peters about patient-centric clinical trial consent forms, an update on the Keynote 604 trial, the importance of women’s sexual health and new data on a combination of therapies for patients with KRAS mutations.
Destacados Diarios WCLC 2022 - 8 de Agosto Es el tercer día de la Conferencia Mundial IASLC 2022 sobre Cáncer de Pulmón! La Dra. Narjust Florez recibe a dos investigadores fundamentales: El Dr. Mariano Provencio y La Dra. Enriqueta Felip, para discutir sus estudios mejor calificados.
It’s Day 3 at the IASLC 2022 World Conference on Lung Cancer! Dr. Narjust Florez hosts pivotal researchers Dr. Enriqueta Felip, Dr. Mariano Provencio, and Dr. Rachael Murray to discuss their top-rated studies. IASLC President Dr. Heather Wakelee also joins in to give insight on how the committee selected these high-ranked abstracts for this year’s Presidential Symposium.
In this special edition of Lung Cancer Considered recorded at the IASLC 2022 World Conference on Lung Cancer, hosts Dr. Narjust Florez and Dr. Stephen Liu interview researchers Dr. Chi-Fu Jeffrey Yang, Dr. Jarushka Naidoo and Mr. Koen de Nijs, PhD student, to discuss their recent findings from the significant studies presented today.
Today's podcast originates from the IASLC World Conference on Lung Cancer in Vienna. Hosts Dr. Stephen Liu and Dr. Narjust Florez interview IASLC WCLC 2022 Honorary Chair Dr. Robert Pirker and Chair Dr. Silvia Novello at the meeting. Dr. Pirker and Dr. Novello provide an overview of the meeting and give podcast listeners a glimpse of what to expect at the IASLC WCLC 2022.
On this episode of Lung Cancer Considered, three past IASLC Fellowship Grants winners share their own stories of how these grants helped propel their careers. Hosted by Dr. Narjust Florez, guests include:
Dr. Grace Dy is an associate professor of medicine at Department of Medicine at Jacobs School of Medicine & Biomedical Sciences at the University of Buffalo and a medical thoracic oncologist at Roswell Park Cancer Center. Dr. Dy received an IASLC fellowship grant in 2007.
Fred R. Hirsch, MD, PhD, is Executive Director at the Center for Thoracic Oncology in The Tisch Cancer Institute at Mount Sinai (TCI) and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. He is also Associate Director of Biomarker Discovery for TCI and a previous CEO of the IASLC. Dr. Hirsch received an IASLC fellowship grant in 2001.
Dr. Jarushka Naidoo is a medical oncologist at Beaumont Hospital in Dublin, Ireland, and an assistant professor at John Hopkins. She is a clinical/translational investigator, specializing in immunotherapy for lung cancer, and immune-related toxicity. Dr. Naidoo received an LCFA/BMS/ILCF Young Investigator Grant in 2020.
The IASLC World Conference on Lung Cancer will be held in person this year in Vienna. Lung Cancer Considered Hosts Dr. Narjust Florez and Dr. Stephen Liu preview the meeting highlights and provide advice on how to plan your own experience and what scientific sessions might be the most interesting. This podcast episode is a must listen for all in person attendees and those participating virtually from their home or office.
In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of the unique challenges women in oncology face as they navigate career pathways. She is joined by Dr. Prunella Blinman, a medical oncologist at Concord Repatriation General Hospital in Sydney, Australia and clinical associate professor at the University of Sydney. Also joining the discussion is Dr. Clarissa Mathias, medical oncologist and director of NOB/Oncoclinicas in Brazil. She is a member of the ASCO International Quality Steering Group and Lung cancer committee and she served on the IASLC board of directors.
In keeping with IASLC's international focus, this episode of Lung Cancer Considered focuses on the state of lung cancer in Germany. This episode is hosted by Dr. Alessandra Curioni, Thoracic Medical Oncologist at the University of Zurich and her guests are two of the most prominent lung cancer experts in Germany -- Dr. Martin Reck, Head of the Department of Thoracic Oncology and the Head of the Clinical Trials Department at the Lung Clinic Grosshansdorf and Dr. Juergen Wolf, Medical Director for the Center for Integrated Oncology at the University Hospital Cologne.
This episode of Lung Cancer Considered examines the state of lung cancer care and research in South Africa. Joining host Dr. Stephen Liu is Dr. Ronwyn van Eeden, a medical oncologist practicing in Rosebank, South Africa. Dr. van Eeden has just started her own oncology unit and is also an honorary consultant in medical oncology at the Chris Hani Baragwanath Academic Hospital.
Dr. Marina Garassino and Dr. Suresh Ramalingam join Lung Cancer Considered host Dr. Narjust Florez to share experiences as international medical graduates.
Dr. Garassino is an internationally recognized expert in the treatment of thoracic malignancies from the Medical School of Università degli Studi of Milan, Italy, She recently joined the University of Chicago as the chief of the Thoracic Oncology Group.
Dr. Suresh Ramalingam is the Executive Director, Winship Cancer Institute of Emory University, the Roberto C. Goizueta Distinguished Chair for Cancer Research, and a professor of medicine at Emory University School of Medicine.
In this episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss the recently completed ASCO meeting with colleagues Dr. Catherine Shu and Dr. Jack West. Dr. Shu is a board-certified medical oncologist specializing in the treatment of thoracic cancers, especially lung cancer, at Columbia University's Herbert Irving Comprehensive Cancer Center. Dr. West is a medical oncologist at City of Hope Cancer Center and is the founder of the Global Resource for Advancing Cancer Education, a nonprofit organization dedicated to providing timely, free, credible information to patients and caregivers around the world.
What are Antibody Drug Conjugates, and do they have a promising future in lung cancer treatment? To discuss this topic, Lung Cancer Considered host Dr. Stephen Liu is joined by Dr. Rebecca Heist, associate director of clinical research at Massachusetts General Hospital Cancer Center in Boston, and Dr. Ben Levy, clinical director of medical oncology at the Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center in Baltimore.
India is an extremely diverse and populous country with just under 1.5 billion people. And as with every country in the world, lung cancer represents a major threat to public health. In this episode of Lung Cancer Considered, host Dr. Stephen Liu talks about the state of lung cancer in India with Dr. Navneet Singh, Professor in the Department of Pulmonary Medicine at the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh, India.
Providing smoking cessation without contributing to the stigma faced by those who smoke is a worthwhile goal. To discuss this in greater detail, Lung Cancer Considered host Dr. Narjust Duma welcomes Dr. Jamie Ostroff, Dr. Matthew Steliga, and Jim Pantelas. Dr. Ostroff is the Joseph Gaumont Chair of Cancer Prevention and the Director of the Memorial Sloan Kettering Tobacco Treatment Program and Dr. Steliga is an Associate Professor in Surgery at the University of Arkansas Medical Center and a member and past chair of the IASLC Tobacco control and smoking cessation committee. Mr. Jim Pantelas is a patient advocate and activist who collaborates with organizations like the Lung Cancer Research Foundation (formerly known as Free to Breathe) and the Lung Cancer Alliance.
Dr. Hilary Robbins, an epidemiologist with the International Agency for Research on Cancer, and Dr. Brendon Stiles, chief of Thoracic Surgery and Surgical Oncology at Montefiore-Einstein Cancer Center in New York, join Lung Cancer Considered host Dr. Stephen Liu to discuss the current status of lung cancer screening research and challenges to implementing it on a national and international scale.
On a special Earth Day episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by two vocal IASLC members who have taken a passionate interest in understanding more about the climate crisis and how it impacts our patients with lung cancer.
In the 100th episode of IASLC's Lung Cancer Considered, host Dr. Narjust Duma interviews new IASLC CEO, Dr. Karen Kelly. Dr. Kelly is recognized internationally for her expertise in lung cancer research and her career has been dedicated to providing enhanced cancer care through innovative and groundbreaking clinical trials. Dr. Kelly’s lung cancer research has involved all aspects of the disease from risk reduction to screening to treatment. She has been at the forefront of drug development to treat lung cancer for decades. Dr. Kelly is the first female to hold this post in the association’s almost 50-year history.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recently completed European Lung Cancer Congress. His guests include Dr. Lizza Hendriks, assistant professor at Maastricht University in the Netherlands. Dr. Hendriks is also a pulmonologist specializing in thoracic oncology and the program leader of the Innovative Cancer Diagnostics Therapy group at GROW School of Oncology. Joining Dr. Hendriks is Dr. Nicolas Girarda, professor of Respiratory Medicine at the Versailles Saint Quentin University and head of the Curie-Montsouris Thorax Institute in Paris.
In this episode of Lung Cancer Considered, host Dr. Narjust Duma talks with Dr. Robert C. Doebele, Co-Founder and Chief Scientific Officer, Rain Therapeutics about NTKR gene fusions, including recent and emerging breakthrough therapies.
The IASLC Targeted Therapies Meeting has historically been a very interactive, fast-paced meeting that highlights the latest and most innovative anticancer drugs, initially focused on targeted agents but in recent years, extending to immunotherapy.
In this Lung Cancer Considered podcast hosts Dr. Narjust Duma and Dr. Stephen Liu lead a wide-ranging discussion of the meeting with three lung cancer experts who attended the meeting:
Dr. Lecia Sequist is a thoracic medical oncologist at Massachusetts General Hospital, the Landry Family Professor of Medicine at Harvard Medical School, the Director of the Center for Innovation in Early Cancer Detection and a board member of the IASLC.
Ivy Elkins was diagnosed with Stage IV lung cancer in Dec 2013 as a healthy 47-year-old, Ivy was found to have an EGFR mutation and has spent the years since her diagnosis educating herself and advocating for herself and those within the lung cancer community. Ivy is a patient advocate and co-founder of the EGFR Resisters Lung Cancer Patient Group.
Dr. Charu Aggarwal is a thoracic medical oncologist at the Hospital of the University of Pennsylvania and the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania.
Neurotrophic tyrosine receptor kinase fusion, or NTRK, has emerged in the last six years as a rare, but targetable alteration in several cancers. Dr. Herbert Loong, clinical assistant professor in the department of clinical oncology and deputy medical director of the Phase 1 Clinical Trials Center of The Chinese University of Hong Kong, joins Lung Cancer Considered host Dr. Stephen Liu to discuss NTRK and what impact it may have on lung cancer research and treatment.
Lung Cancer Considered hosts Dr. Narjust Duma and Dr. Stephen Liu discuss ALK-fusion positive NSCLC with Dr. Jessica Lin, a physician at the Massachusetts General Hospital Cancer Center and an Assistant Professor of Medicine at Harvard Medical School, and Dr. Ben Solomon, a professor and consultant medical oncologist at Peter MacCallum Cancer Center in Melbourne, Australia.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu talks with Dr. Zosia Piotrowska, Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital in Boston, Mass., about the current and future state of therapies for patients with EGFR mutant lung cancer.
Cell therapy has made strides in hematology and oncology and has recently shown promise in thoracic oncology. In this episode of Lung Cancer Considered host, Dr. Narjust Duma delves into this emerging therapy with guests Dr. Ben Creelan, associate professor of medicine at the University of South Florida, thoracic oncologist at Moffitt Cancer Center and Dr. Prasad Adusumilli, deputy chief and attending of the thoracic service, vice chair for translational research in the department of surgery at Memorial Sloan Kettering Cancer Center.
This episode of Lung Cancer Considered focuses on an EGFR mutant non-small cell lung cancer virtual tumor board case that involves a 41-year-old woman who is a never smoker and presents with a dry cough, chest pain, and weight loss. Discussing treatment options on this podcast with host Dr. Narjust Duma are Dr. Alfredo Addeo, senior oncologist at Geneva Hospital in Geneva, Switzerland, and Dr. Helena Yu, medical oncologist at Memorial Sloan Kettering Cancer Center in New York City.
Dr. Jacques Cadranel, Head of Department Pulmonology and Thoracic Oncology, Assistance Publique Hôpitaux de Paris and Sorbonne University and Dr Janessa Laskin, Medical Oncologist at the Vancouver Cancer Centre in British Columbia, Canada join Lung Cancer Considered Host Dr. Narjust Duma to discuss current and promising breakthrough therapies in lung cancer.
Dr. Narjust Duma hosts a spirited Spanish-language edition of Lung Cancer Considered on the recently completed 2021 LALCA Schools of Thoracic Oncology meeting with Luis E. Raez, MD, Chief Scientific Officer & Medical Director Memorial Cancer Institute/Memorial Health Care System; Lucia Viola, MD, Interventional Pulmonologist, Head of Thoracic Oncology Service, Fundación Neumológica Colombiana and Christian Rolfo, MD, PhD, Professor and Assoc. Director for Clinical Research, Center for Thoracic Oncology- Icahn School of Medicine at Mount Sinai.
La Dra. Narjust Duma presenta una animada edición en español de Lung Cancer Considered durante la reunión de las Escuelas de Oncología Torácica LALCA 2021 recientemente completada, con el Dr. Luis E. Raez, Director Científico y Médico del Memorial Cancer Institute / Memorial Health Care System; Dra. Lucia Viola, Neumóloga Intervencionista, Jefa del Servicio de Oncología Torácica, Fundación Neumológica Colombiana y el Dr. Christian Rolfo, Profesor y Asociado. Director de Investigación Clínica, Centro de Oncología Torácica - Facultad de Medicina Icahn en Mount Sinai.
Lung Cancer Considered host Dr. Stephen Liu discusses a virtual tumor board with guests Dr. Anthony Kim, professor of clinical surgery and chief of thoracic surgery at The Keck School of Medicine at the University of Southern California and Dr. Patricia Rivera, professor of medicine at University of North Carolina and director of the UNC Lung Cancer Screening Initiative. The case involves a 45-year-old woman with stage III non-small cell lung cancer.
In this new episode of Lung Cancer Considered, podcast host Dr. Narjust Duma interviews three IASLC Patient Research Advocates who are part of the IASLC Supportive Training for Advocates on Research & Science (STARS) program: Caleb Egwuenu comes from Nigeria and participated in STARS for two years as a Patient Research Advocate: Erika Hlavacek, a Patient Research Advocate and founder of nonprofit yEAHbestlife from Illinois; and Lillian Leigh, STARS mentor from Australia.
Globally, lung cancer is the single most lethal cancer, accounting for 1.8 million deaths last year, yet research funding devoted to lung cancer pales in comparison to other cancer types. In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses how global advocacy might play a role in addressing this gap. His guest is Dr. Anne-Marie Baird, a cancer researcher at Trinity College in Dublin, Ireland. Dr. Baird is the former Chair of the IASLC Communications Committee, and the newly appointed President of Lung Cancer Europe, a European platform for lung cancer advocacy.
In a special Korean-language Lung Cancer Considered episode, leading lung cancer specialists discuss the state of the disease in South Korea. Host Dr. Chul Kim, assistant professor of Medicine and Thoracic Medical Oncologist at Georgetown University, interviews Dr. Young Tae Kim, professor of the Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine and Dr. Sun Min Lim, assistant professor of the Department of Internal Medicine, Yonsei University College of Medicine. The podcast will be released in conjunction with the annual meeting of the Korean Association for Lung Cancer held on November 25-26, 2021 in Seoul, South Korea (https://www.kalcic.or.kr/main.php).
세계폐암학회에서 주관하는 팟캐스트인 'Lung Cancer Considered'에서 폐암 전문가들을 모시고 한국 특별편을 준비하였습니다. 조지타운대학교 암센터에서 폐암 전문의로 근무하고 있는 김철 교수가 서울대학교병원 흉부외과 김영태 교수님과 연세대학교 의과대학 내과학교실 종양내과 임선민 교수님을 모시고 인터뷰를 진행하였습니다. 이번 한국 특별편 팟캐스트는 11월 25일과 26일에 서울에서 열리는 대한폐암학회 국제학술대회 (https://www.kalcic.or.kr/main.php)에 맞춰 공개될 예정입니다.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on a virtual tumor board case focusing on a patient with stage III NSCLC. Guests are Dr. Erin Gillaspie, assistant professor of Thoracic Surgery at Vanderbilt University in Nashville, Tenn., and Dr. Shankar Siva, associate professor at the University of Melbourne, in Victoria, Australia.
Professional Golfer Jason Day has known success in his career--he has been the top ranked PGA player and won the PGA Championship in 2015. Unfortunately, that year Jason’s mother Denning was diagnosed with state IV non-small-cell lung cancer, spurring Jason to become a passionate advocate for lung cancer research and treatment. Tune into this episode of Lung Cancer Considered to hear about how he became a lung cancer advocate and how his mother’s health drove him to become an advocate for biomarker testing.
In this episode of Lung Cancer Considered, host Dr. Narjust Duma talks with Heidi Nafman-Onda and her husband Dr. Pierre Onda, the founders of The White Ribbon project, and patient advocate/activist Chris Draft from the Chris Draft Family Foundation.
This episode of Lung Cancer Considered looks ahead to the IASLC 2021 Hot Topic Meeting on Small Cell Lung Cancer, scheduled for Oct 29th and 30th 2021. Host Dr. Stephen Liu discusses the state of the SCLC research with Dr. Tripnara Sen, an Assistant Attending Biologist in the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center and Dr. Charles Rudin, the co-director of the Druckenmiller Center for Lung Cancer Research and the Sylvia Hassenfeld Chair in Lung Cancer Research, also from Memorial Sloan Kettering.
Tune in to Lung Cancer Considered as host Dr. Stephen Liu discusses a virtual tumor board case involving a patient with small cell lung cancer. Guests include Dr. Lauren Byers, associate professor of Medicine at The University of Texas MD Anderson Cancer Center, and Dr. Ponce Aix, from the Gustave Roussy in Paris, France.
In this episode of Lung Cancer Considered, podcast guests Dr. Solange Peters, current ESMO president, and Dr. Pasi Janne, co-chair of ESMO 2021, discuss the recently concluded ESMO meeting and share the meeting’s most significant lung cancer research findings with podcast host Dr. Narjust Duma.
The intersection of medicine and politics is fascinating and often controversial and contentious. In this episode of Lung Cancer Considered, host Dr. Stephen Liu talks to two physicians who have entered the political arena—Dr. Nasser Hanna, who ran in Indiana’s 5th Congressional District and Dr. Raja Flores, who is running for Mayor of New York City.
In this episode of Lung Cancer Considered, Dr. Nathan Pennell, from the Cleveland Clinic, and Podcast host Dr. Narjust Duma, from Dana Farber Cancer Institute, share information about how lung cancer care has changed in the 14 years Dr. Pennell has been in practice.
The IASLC 2021 World Conference on Lung Cancer co-chairs Dr. David Harpole, Dr. Kristin Higgins, Dr. Thomas Stinchcombe join Lung Cancer Considered Hosts Dr. Narjust Duma and Dr. Stephen Liu to cover highlights of the recently concluded virtual meeting. Tune in to hear these IASLC members discuss the most significant research developments from the conference.
In this episode of Lung Cancer Considered , Dr. Heather Wakelee and Dr. Paul Van Schil join hosts Dr. Narjust Duma and Dr. Stephen Liu to discuss priorities and initiatives for IASLC in the 2021-22 year. Dr. Wakelee takes the reins as President of the IASLC this month during WCLC, the second woman to achieve this honor. Dr. Van Schil begins his term as President-Elect of the IASLC during WCLC, too.
In this episode of Lung Cancer Considered, host Dr. Narjust Duma and Dr. Ibiayo Dagogo discuss BRAF mutated non-small cell lung cancer and some unique characteristics of patients with this mutation.
About 20 percent of breast cancer cases have a link to the protein HER2, but HER2's link to lung cancer is not as common, and effective therapies have eluded lung cancer researchers. To learn more about the state of HER2 research for lung cancer, listen to this episode of Lung Cancer Considered with host Dr. Stephen Liu and Dr. Bob T. Li, Medical Oncologist from Memorial Sloan Kettering.
In this episode of Lung Cancer Considered, host Dr. Stephen Liu and guests Dr. Misako Nagasaka and Dr. Antonio Passaro discuss management of a Stage IV non-small cell lung cancer in this Virtual Tumor Board case study.
In this special musical edition of Lung Cancer Considered, Host Stephen Liu talks with physician-researcher and musician Dr. Thomas John from Melbourne, Australia. We think you’ll want to tune in and listen to the end as Dr. John, performing as Mayhemtom, shares his new single called ‘Reach Out’ from the album he is currently producing. The single is now available at: https://linktr.ee/mayhemtom
Review: https://beat.com.au/mayhemtom-funnels-existential-drama-into-dreamy-indie-rock-on-his-debut-single-reach-out/
In this special Italian-language edition of Lung Cancer Considered, host Dr. Alfredo Addeo examines lung cancer in Italy with Dr. Marina Garissino and Dr. Silvia Novello. The researchers discuss their thoughts on navigating a career as women oncologists in Italy and compare their perceptions about the differences in lung cancer screening and research between Italy and other countries.
In this edition of Lung Cancer Considered, host Narjust Duma and Dr. Fumiko Chino discuss a challenge to thoracic oncology which is financial toxicity associated with cancer care. The two women dive into the complexity of health insurance and the multifactorial situations that are associated with the care a patient receives. Dr. Chino also reveals her personal experience with financial toxicity and a cancer diagnosis of a family member.
The American Society of Clinical Oncology meeting just concluded and Lung Cancer Considered has a summary of the meeting, with a unique lung cancer focus. Tune in as host Stephen Liu and guests Dr. Alfredo Addeo and Dr. Heather Wakelee discuss key findings from ASCO 2021.
In this edition of Lung Cancer Considered, host Dr. Narjust Duma discusses the use of neoadjuvant immunotherapy, through a multidisciplinary lens, with guests Dr. Leah Backhus and Dr. Patrick Forde.
In this episode of Lung Cancer Considered, Dr. Stephen Liu sits down with guest Dr. Harpreet Singh from the FDA to discuss the agency’s oncology drug approval process. The interview also covers how new drug approvals are handled in other countries
In this episode of Lung Cancer Considered, guests Dr. Kristin A. Higgins and Dr. Antonio Calles discuss the case of a 42-year-old woman who presents to the emergency room with right shoulder pain and a dry cough that has worsened over the previous two months. A CT scan reveals she has a four-centimeter mass in her right lobe. Her PDL-1 is 1-2 percent. She has a limited history of smoking but no co-morbidities but she has lost 10 pounds since she was first seen in the emergency room.
This new episode of Lung Cancer Considered features a discussion of the seminal trial KEYNOTE 001 and how it impacted research and clinical care for patients with lung cancer. This podcast is noteworthy because, in addition to including researcher Dr. Eddie Garon, it also features the unique perspective from Cary Parton, a patient who participated in this trial.
This episode of Lung Cancer Considered covers recent promising results with new targeted agents for NSCLC harboring a KRAS G12C mutation. Thoracic oncologists have long thought this condition was undruggable, but results presented at WCLC 2020 from the CodeBreak 100 trial provide hope that new therapies will be more readily available.
The latest edition of Lung Cancer Considered features a discussion on a virtual tumor board in mesothelioma, involving a case with a 68-year-old male, with 30 pack years smoking history who presents to the ER due to a worsening shortness of breath at rest and with exertion, unresectable mesothelioma with chest wall invasion and pleural effusion thickening with enlarged mediastinal lymph nodes and right chest wall invasion. Thoracentesis revealed a serosanguineous fluid (removed 1.1 l) with improvement of the respiratory symptoms. Cytology was negative for malignancy. Thoracoscopy is done to obtain pleural biopsies. Listen as guests Dr. Aaron Mansfield and Dr. Anna Nowak discuss the case and offer treatment options.
In this episode of Lung Cancer Considered, Dr. Sai-Hong Ignatius Ou shares his career growth and experience participating and leading breakthrough clinical trials on therapies to treat ALK positive patients with lung cancer. Dr. Ou discusses a pivotal moment at the beginning of his career when he visited the Pfizer campus in California to learn about their effort to develop a phase 1 trial examining MET amplifications and MET mutations. The visit helped spur him to become more involved in lung cancer research.
This edition of Lung Cancer Considered discusses important science presented at the recently completed European Lung Cancer Congress, the multidisciplinary lung cancer meeting co-organized by ESMO and IASLC. Dr. Enriqueta Felip and Dr. Fabrice Barlesi share their interpretation of the following clinical trials presented at ELCC: Adagrasib (MRTX849) -- phase Ib expansion and phase II monotherapy cohorts CheckMate 9LA -- randomized 719 patients with EGFR/ALK wild type NSCLC to standard chemotherapy or 2 cycles of chemotherapy with nivolumab and Ipilimumab KEYNOTE-407-- randomized squamous NSCLC to carboplatin with choice of nab/ paclitaxel or paclitaxel, and either pembrolizumab or placebo AMG 757-- BiTE: bispecific T-cell engager targeting DLL3 and engaging CD3 CAMEL-sq trial-- phase III randomized trial in patients with advanced squamous NSCLC
The latest edition of Lung Cancer Considered features a discussion on a virtual tumor board case involving squamous cell lung cancer. Our guests are Dr. Enriqueta Felip, who is a professor of medicine and section in chief, Medical Oncology and Department Director of Thoracic Oncology at the Vall d’Hebron University Hospital in Barcelona. Joining Dr. Felip is Dr. Paul Paik, an associate attending physician and clinical director, of the Thoracic Oncology Service Department of Medicine Memorial Sloan Kettering Cancer Center in New York.
This special episode of Lung Cancer Considered features a conversation between host Dr. Stephen Liu and co-host Paul Bunn. Dr. Liu and Dr. Bunn are joined by, Dr. Tal Zaks, the chief medical officer at Moderna, and Dr. Amy Moore, a trained virologist and cancer researcher. Dr. Bunn is the founding director of the University of Colorado Cancer Center, former president of IASLC and ASCO. Dr. Moore serves as the director of Science and Research for the GO2 Foundation for Lung Cancer. Together, they discuss the development of the Moderna COVID-19 vaccine what lung cancer patients, doctors and advocates should know.
The latest episode of Lung Cancer Considered features a conversation between host, Dr. Stephen Liu and Dr. Myung-Ju Ahn, professor in the Department of Hematology-Oncology at the Samsung Medical Center, Sungkyunkwan University School of Medicine in South Korea. Together they discuss Dr. Ahn's career and her work in ROS1 lung cancer.
The latest episode of Lung Cancer Considered features a conversation between host Dr. Stephen Liu and Dr. Alex Drilon, chief, early drug development at Memorial Sloan Kettering Cancer Center. Together they discuss Dr. Drilon's career and his work on RET fusions in lung cancer.
The latest episode of Lung Cancer Considered features a conversation between host Dr. Narjust Duma and Dr. Balazs Halmos, professor of oncology and chief, thoracic/head and neck oncology at Montefiore Medical Center/Albert Einstein College of Medicine in New York. Together they discuss Dr. Halmos' career and his work on EGFR mutant non-small cell lung cancer.
Lung Cancer Considered hosts Dr. Stephen Liu and Dr. Narjust Duma are joined by Dr. Ross Soo, a senior consultant in the Department of Hematology-Oncology at the National University of Cancer Institute Singapore to discuss highlights from the IASLC 2020 WCLC Singapore meeting. Dr. Soo, along with Dr. Yi-Long Wu and Dr. Daniel Tan, served as co-chair of the meeting. Together Dr. Liu, Dr. Duma and Dr. Soo discuss key science, highlights, benefits and challenges of the virtual meeting.
Lung Cancer Considered hosts Dr. Stephen Liu and Dr. Narjust Duma share highlights, tips and tricks for navigating IASLC's World Conference on Lung Cancer Singapore this year. Listen to this podcast as you prepare for the world’s leading lung cancer event (held virtually January 28 – 31). Register for IASLC's WCLC at //wclc2020.iaslc.org/registration.
The latest episode of Lung Cancer Considered discusses women in thoracic oncology and the upcoming IASLC Women in Thoracic Oncology Event. Register now for this event. This episode features a conversation between host, Dr. Narjust Duma, and Dr. Heather Wakelee and Dr. Clarissa Mathias. Dr. Wakelee is a thoracic medical oncologist, Deputy Director of the Stanford Cancer Institute and is the Division Chief of Medical Oncology at Stanford University Medical Center. She is also the president-elect of the IASLC. Dr. Clarissa Mathias, Medical Oncologist at Grupo Oncoclinicas, is president of the Brazilian Society of Medical Oncology, Chair of the ASCO International Committee and a member of the IASLC Board of Directors. Together they discuss their career paths and what they are looking forward to at the Virtual Women in Thoracic Oncology Event hosted by IASLC on January 20th.
The latest episode of Lung Cancer Considered introduces its new hosts, Dr. Stephen Liu and Dr. Narjust Duma. Dr. Liu is an associate professor at the Lombardi Cancer Center at Georgetown University School of Medicine. Dr. Duma is an assistant professor of medicine and a thoracic oncologist at the University of Wisconsin. Get to know both Dr. Liu and Dr. Duma a little more and hear what their goals are in 2021 for Lung Cancer Considered.
The latest episode of Lung Cancer Considered discusses biological and molecular staging as a dimension beyond sized-based staging. This episode features a conversation between host Dr. Jack West and Dr. Daniel Boffa, professor and division chief of thoracic surgery at Yale University.
The latest episode of “Lung Cancer Considered” discusses the practice patterns and clinical trials in India and how COVID-19 has impacted the field in India. This episode features a conversation between host Dr. Jack West and Dr. Vanita Noronha, professor of medical oncology at Tata Memorial Hospital, Mumbai, India.
The latest episode of Lung Cancer Considered brings you part two of our conversation on lung cancer stigma during Lung Cancer Awareness Month. This episode features a discussion with Jill Feldman, patient advocate; Terri Conneran, a three-time lung cancer survivor and advocate and director and founder of KRAS Kickers and the director of LiveLung International Relations; Jamie L. Studts, a professor in the division of medical oncology, department of medicine at the University of Colorado School of Medicine; and Mary Pasquinelli, a nurse practitioner in the Pulmonary Division at UI Health at the University of Illinois.
In the latest episode of Lung Cancer Considered, we kick off Lung Cancer Awareness Month focusing on stigma within the lung cancer community and what we can all do to understand and overcome it. This episode features a conversation between Jill Feldman, lung cancer patient advocate and co-founder of EGRF Resisters; Terri Conneran, a three-time lung cancer survivor and advocate and director and founder of KRAS Kickers and the director of LiveLung International Relations; Jamie L. Studts, a professor in the Division of Medical Oncology, Department of Medicine at the University of Colorado School of Medicine; and Mary Pasquinelli, a nurse practitioner in the Pulmonary Division at UI Health at the University of Illinois.
The latest episode of Lung Cancer Considered focuses on the data and clinical outcomes for patients who may go off immunotherapy after two years. This episode features a conversation between host Dr. Jack West and Dr. Matt Hellman, associate attending at Memorial Sloan Kettering Cancer Center.
In the latest episode of Lung Cancer Considered, we're going back to October 2019, pre-COVID, when Dr. Jack West interviewed Dr. Tony Mok about highlights and new research from the 2019 IASLC World Conference on Lung Cancer. We’re feeling nostalgic about being able to meet in person and heartened by how far we’ve come since our last time together.
In the latest episode of Lung Cancer Considered, three experts in thoracic oncology from around the world discuss and share their stories and experience about diversity and equity in medicine. This episode features a conversation between Dr. Narjust Duma, assistant professor of medicine - thoracic oncology at the University of Wisconsin Carbone Cancer Center; Dr. Jhanelle Gray, chair of the department of thoracic oncology and program co-leader for chemical biology and molecular medicine at the Moffitt Cancer Center; and Dr. Clarissa Mathias, Brazilian Society of Medical Oncology president, IASLC Board Member, Chair of the ASCO International Committee and Medical Oncologist at Grupo Oncoclinicas.
The latest episode of Lung Cancer Considered focuses on using digital and social media connections as an educational tool given that COVID-19 has limited in-person interactions. This episode features a conversation between host Dr. Jack West and Dr. Sanjay Mukhopadhyay, director of Pulmonary Pathology at the Cleveland Clinic.
The latest episode of Lung Cancer Considered focuses on the upcoming IASLC Liquid Biopsy Meeting that will discuss the current status of liquid biopsy in the field of thoracic. This episode features a conversation between Dr. David Gandara, director of thoracic oncology, professor emeritus, and senior advisor to the director at the UC Davis Comprehensive Cancer Center; Dr. Maria Arcila, director of the diagnostic molecular pathology laboratory at Memorial Sloan Kettering Cancer Center; and Dr. Christian Rolfo, director of the thoracic medical oncology and early clinical trials at the University of Maryland Comprehensive Cancer Center (UMGCCC), a professor in the division of hematology-oncology at the University of Maryland, and educational chair of the International Society of Liquid Biopsies.
The latest episode of Lung Cancer Considered focuses on the IASLC Pathology Committee's creation of the Immunohistochemistry (IHC) Atlas. This episode features a conversation between host Dr. Sanja Dacic, a professor in the department of pathology at the University of Pittsburg Medical Center in Pennsylvania; Dr. Keith Kerr, professor of pulmonary pathology at Aberdeen University Medical School and a consultant pathologist at the Aberdeen Royal Infirmary in Scotland; and Dr. Yasushi Yatabe, chief of the department of diagnostic pathology at the National Cancer Center in Toyko, Japan.
The latest episode of Lung Cancer Considered focuses on a recent article in the IASLC Lung Cancer News publication about the pros and cons of telemedicine. This episode features a conversation between host Dr. Jack West and Dr. Mary Jo Fidler, associate professor of medical oncology at Rush Medical University Center in Chicago and Dr. Sandip Patel, associate professor of medical oncology at the University of California at San Diego.
The latest episode of Lung Cancer Considered focuses on the research from the ADAURA trial that came out of ASCO 2020. This episode features a conversation between IASLC Chief Science Officer, Dr. Chandra Belani; Dr. Nathan Pennell, professor of medicine and director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute; Dr. Jack West, an associate clinical professor in medical oncology, a specialist in thoracic oncology and executive director of employee services at City of Hope of Comprehensive Cancer Center; and Jill Feldman, lung cancer patient, patient advocate and co-founder of the group EGFRResisters.
The latest episode of Lung Cancer Considered focuses on a recent publication in IASLC's Journal of Thoracic Oncology that features new guidelines on Tumor Mutational Burden as well as the effects of COVID-19. This episode features a conversation between host Dr. Marty Edelman; Dr. Lynette Scholl an associate professor of Pathology at Harvard Medical School and an associate pathologist, Pathology at Brigham And Women's Hospital; and Dr. John Longshore director of Molecular Pathology at Carolinas Pathology Group, Atrium Health, Carolinas HealthCare System.
The latest episode of Lung Cancer Considered focuses on the virtual format of the ASCO Annual meeting, implications for COVID-19 for how scientific and educational conferences will be structured and the power of social media during a pandemic. This episode features a conversation between host Dr. Jack West and Dr. Tatiana Prowell, associate professor of oncology in the breast cancer program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Under Armour Breast Health Innovation Center and breast cancer scientific liaison at the U.S. Food and Drug Administration.
The latest episode of Lung Cancer Considered is a post- AACR debrief focusing on MET testing, TERAVOLT data and life in NYC during COVID-19. This episode features a conversation between host Dr. Jack West and Dr. Greg Riely, vice chair of clinical research in the department of medicine at Memorial Sloan Kettering Cancer Center in New York.
The latest episode of Lung Cancer Considered focuses on lung cancer research presented at the American Society of Clinical Oncology virtual meeting this past weekend. This episode features a conversation between IASLC Chief Science Officer, Dr. Chandra Belani and Dr. Stephen Liu, associate professor at the Lombardi Cancer Center at Georgetown University School of Medicine.
The latest episode of Lung Cancer Considered features a conversation between host Dr. Jack West and Dr. Corinne Faivre-Finn, professor of thoracic radiation oncology and honorary consultant clinical oncologist at the Christie National Health Service Foundation Trust in the United Kingdom and Dr. Walter J. Curran, Jr., executive director of the Winship Cancer Institute of Emory University and the Lawrence W. Davis professor and chairman of the Emory Department of Radiation Oncology. The podcast focuses on radiation oncology, lung cancer and COVID-19.
The newest episode of Lung Cancer Considered, the IASLC's official podcast program, features patient advocates and lung cancer researchers on what patients need to know about lung cancer research in the era of COVID-19. This episode features a conversation between Janet Freeman-Daily, writer, lung cancer patient, advocate and Twitter chat moderator of the Lung Cancer Social Media chat (#LCSMchat); Jill Feldman, lung cancer advocate and patient; Dr. Alice Berger, assistant professor of human biology at the Fred Hutchinson Cancer Research Center; Dr. Christine Lovly, associate professor of medicine, division of Hematology and Oncology and Ingram Associate Professor of Cancer Research at Vanderbilt University Medical Center; Dr. Brendon Stiles, associate professor of cardiothoracic surgery at Weill Cornell Medical College, Cornell University, and the associate attending cardiothoracic surgeon at New York Presbyterian Hospital; Dr. Amy Moore has experience as a cancer researcher as director of science and research at the GO2 Foundation for Lung Cancer; Dr Upal Basu Roy also has experience as a cancer researcher as vice president of research at LUNGevity Foundation; and Dr Jan Baranski, vice president of scientific and patient programs for the Lung Cancer Research Foundation.
The newest episode of Lung Cancer Considered, the IASLC's official podcast program, focuses on a discussion between lung cancer experts from the U.S. and Europe discussing COVID-19 with regard to lung cancer patients with experiences, results and actions from different parts of the world. This episode features a conversation between Dr. Marty Edelman, chair of department of hematology/oncology and a professor, department of hematology/oncology at Fox Chase Cancer Center; Dr. Leora Horn, Ingram associate professor of cancer research at Vanderbilt Ingram Cancer Center and clinical director, thoracic oncology program; and Dr. Solange Peters, professor and chair of thoracic oncology at the University of Hospital Lausanne (CHUV), and current president of ESMO.
The newest episode of Lung Cancer Considered, the IASLC's official podcast program, is a Spanish language podcast focusing on the use of telemedecine during this time and how lung cancer patients can find information in different regions of the world. This episode features a conversation between Dr. Narjust Duma, assistant professor of medicine, thoracic oncologist at the University of Wisconsin; Dr. José Corona-Cruz, thoracic surgical oncologist at the Instituto Nacional de Cancerología in México; and Dr. Antonio Calles, medical oncologist in the Division of Medical Oncology at the Hospital General Universitario Gregorio Marañón in Madrid, Spain.
The newest episode of Lung Cancer Considered, the IASLC's official podcast program, focuses on a collection of journal articles and guidelines about COVID-19 in patients with lung cancer. This episode features a conversation between IASLC Chief Science Officer, Dr. Chandra Belani and Dr. Erin Bange, oncology fellow of the University of Pennsylvania School of Medicine.
The newest episode of Lung Cancer Considered, the IASLC's official podcast program, focuses on the recent Journal of Thoracic Oncology study, "Potential Impact of Cessation Interventions at the Point of Lung Cancer Screening on Lung Cancer and Overall Mortality in the United States." This episode features a conversation between Dr. Jack West and Dr. Rafael Meza, associate professor in the department of epidemiology and co-leader of the cancer epidemiology and prevention program at the University of Michigan Rogel Cancer Center.
This episode features Dr. Shu-Yuan Xiao, professor of pathology at the University of Chicago and Lung Cancer Considered host Dr. Jack West discussing a COVID-19 report that was recently published in the Journal of Thoracic Oncology. The study covers the pathology of two COVID-19 positive patients from Wuhan who were originally treated for lung cancer.
This episode features Janet Freeman- Daily, writer, lung cancer patient, advocate and Twitter chat moderator of the Lung Cancer Social Media chat (#LCSMchat), she is joined by Dr. Amy Moore, Director of Science and Research at the Go2 Foundation, Dr. Upal Basu Roy, Vice President of Research at LUNGevity Foundation, and Dr. Lecia Sequist, Director of Center for Innovation and Early Cancer Detection at Massachusetts General Hospital and the Landry Family Associate Professor of Medicine at Harvard Medical School. Together they discuss the impact of the COVID-19 epidemic on lung cancer patients and healthcare providers.
This episode features a conversation between Dr. Marty Edelman, Chair of the Department of Hematology/Oncology and a Professor, Department of Hematology/Oncology at Fox Chase Cancer Center and IASLC President, Dr. Tetsuya Mitsudomi, a Professor at the Division of Thoracic Surgery, Department of Surgery at Kindai University Faculty of Medicine in Osaka-Sayama, Japan. Together they discuss highlights of Dr. Mitsudomi's career, his goals as President of IASLC and what his hopes are for the future of lung cancer research.
This episode features Dr. Marty Edelman, Chair of the Department of Hematology/Oncology and a Professor, Department of Hematology/Oncology at Fox Chase Cancer Center. He is joined by Dr. Roy Herbst, a Professor of Medicine and Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center/ Yale School of Medicine; and Dr. Leora Horn, the Ingram Associate Professor of Cancer Research at Vanderbilt Ingram Cancer Center and Clinical Director, Thoracic Oncology Program. Together they discuss highlights from the 20th IASLC 2020 Lung Cancer Targeted Therapies conference in Santa Monica
This episode features Janet Freeman- Daily, writer, lung cancer patient, advocate and Twitter chat moderator of the Lung Cancer Social Media chat (#LCSMchat), she is joined by Dr. Paul Bunn, a distinguished professor and Dudley Endowed Chair at the University of Colorado Comprehensive Cancer Center and IASLC Past President and Past CEO; as well as Dr. Suresh Ramalingam, Roberto Goizueta Chair in Cancer Research, Winship Cancer Institute of Emory University. Together they discuss the upcoming IASLC 2020 Lung Cancer Targeted Therapies meeting in Santa Monica.
This episode features a conversation between Dr. Heather Wakelee, Professor of Medicine in the Division of Oncology at Stanford University and faculty director of the Stanford Cancer Clinical Trials Office and current president-elect of the IASLC and Dr. Chandra Belani, professor of Medicine in the Division of Hematology/Oncology in the Department of Medicine at the Penn State Hershey Medical Center in Hershey, Penn. The interview covers Dr. Belani’s new position as chief science officer for the IASLC and the history of his involvement with lung cancer.
This episode features a conversation between Dr. Heather Wakelee, professor of Medicine in the Division of Oncology at Stanford University and faculty director of the Stanford Cancer Clinical Trials Office and current president-elect of the IASLC and Dr. Chandra Belani, professor of Medicine in the Division of Hematology/Oncology at the Penn State Hershey Medical Center in Hershey, Penn., and the chief science officer for the IASLC. Together they discuss a recent study from the American Cancer Society that reported a significant drop in the cancer mortality rate, led largely by progress in lung cancer.
This episode features a conversation between David Mesko, the chief executive officer of IASLC and Dr. Matt Steliga, chair of The IASLC Tobacco Control and Smoking Cessation Committee and surgical oncologist at Winthrop P. Rockefeller Cancer Institute, Little Rock, Ark. The two discussed the e-cigarettes and vaping and IASLC’s leadership on this developing public health issue.
Patrick Connor, from Astrazeneca and Maureen Rigney, from G02 Foundation for Lung Cancer, join Dr. Jack West to discuss the formation of the Lung Ambition Alliance. To learn more about Lung Ambition, listen to the podcast and visit https://www.lungambitionalliance.com/
Dr. Vershalee Shukla, radiation oncologist at the Vincere Cancer Center in Scottsdale, Ariz., joins Dr. Jack West to discuss what led her to pursue research on lung cancer for first responders that she presented at the IASLC 2019 North American Conference on Lung Cancer in Chicago.
Dr. Benjamin Besse, medical oncologist and head of thorocacic onoclogy program at the Institut Gustave Roussy, France, joined Dr. Jack West at the IASLC World Conference on Lung Cancer in Barcelona, Spain discuss lung cancer research trends in France.
Lung cancer survivors Montessa Lee and Janet Freeman Daily join Dr. Jack West to discuss their stories coping with lung cancer, becoming patient advocates and what advice they have for lung cancer patients.
Dr. Heather Wakelee thoracic medical oncologist and professor of medicine at Stanford University Medical Center and president-elect of IASLC and Corinne Faivre-Finn professor of thoracic radition oncology at the University of Manchester in the UK and honorary consultant clinical oncologist joined Dr. Jack West at the IASLC World Conference on Lung Cancer in Barcelona, Spain to discuss women leadership in oncology and medicine.
Dr. Tony Mok, Li Shu Fan Medical Foundation professor of clinical oncology in the department of Clinical Oncology at the Chinese University of Hong Kong, joined Dr. Jack West at the IASLC World Conference on Lung Cancer in Barcelona, Spain discuss highlights and new research from the conference. Dr. Mok is a past president of IASLC.
Dr. Benjamin Solomon, lead investigator and medical oncologist at Peter MacCallum Cancer Centre, Melbourne, Australia joined Dr. Jack West at the IASLC World Conference on Lung Cancer in Barcelona, Spain to discuss his journey to thoracic oncology, why he chose to focus on Alk+ Non- Small Cell Cancer and lung cancer trends Australia.
Dr. Ramon Rami Porta, Clinical Chief of the Department of Thoracic Surgery at Hospital Universitari Mútua Terrassa, in Terrassa (Barcelona), Spain, joins Dr. Jack West for a discussion on the importance of lung cancer tumor staging, the status of CT Screening for lung cancer prevention in Europe and a preview of the IASLC World Conference on Lung Cancer in Barcelona. Listen to the end to get some tips on Barcelona culture, food and a great tip for waking up in the morning after a late dinner!
Dr. Jack West is joined by Dr. Christine Lovly to discuss highlights from the 2019 ASCO Annual Meeting. Dr. Lovly is associate professor of medicine at Vanderbilt University Medical Center in Nashville, Tennessee.
Dr. Jack west is joined by Dr. Alex Adjei, Professor of Medicine, Professor of Medical Oncology and Editor-in-Chief at the Journal of Thoracic Oncology. Dr. West and Dr. Adjei discuss the evolution of the Journal of Thoracic Oncology and the impact it has on lung cancer awareness for professionals.
Dr. Jack West is joined by Dr. Alexander Drilon to discuss the challenge of NGS testing and increased participation and funding in lung cancer clinical trials. Dr. Drilon is Associate Attending Physician and Clinical Director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center in New York. Dr. Drilon has been at the forefront of development of many novel targeted therapies for some of the newest biomarker-driven therapies for advanced non-small cell.
Dr. Jack West is joined by Dr. Anne Tsao for a conversation on the state of treatment of mesothelioma in anticipation of the first IASLC 2019 Mesothelioma Meeting July 10-12, 2019 in New York, NY. Dr. Tsao is Professor in the Department of Thoracic Head and Neck Medical Oncology in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston. She is also Director of the Mesothelioma Program and Director of the Thoracic Chemo Radiation program.
Dr. Jack West is joined by Dr. Corey Langer to discuss lung cancer management, niche patients including PS2 and elderly patients, the evolution of small cell lung cancer treatment and care, and chemo immunotherapy. Dr. Langer is Director of Thoracic Oncology and Professor of Medicine at the Hospital of the University of Pennsylvania in Philadelphia.
Dr. Jack West is joined by Dr. Walter J. Curran for discussions on radiation oncology, immunotherapy and the interaction with radiation, and the evolution of proton therapy including growth of the field and access to treatment. Dr. Curran is Executive director of the Winship Cancer Institute of Emory University and current chair of the NRG Oncology Group.
Dr. Jack West is joined by Dr. David Spigel to discuss medication for lung cancer treatment, checkpoint inhibitor therapy and the future of duration of treatment for lung cancer patients. Dr. Spigel is Chief Scientific Officer at Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Spigel is a medical oncologist with a particular focus on thoracic oncology.
IASLC CEO Dave Mesko sits down with IASLC President-Elect candidate, Dr. Heather Wakelee, Professor of Medicine, Oncology at Stanford University in Stanford, California. Voting is available to active IASLC members and ends at 11:59 Eastern Time on June 26, 2019. Vote at directvote.net/IASLC.
IASLC CEO Dave Mesko sits down with IASLC President-Elect candidate, Dr. William Travis, Attending Thoracic Pathologist at Memorial Sloan Kettering Cancer Center in New York. Voting is available to active IASLC members and ends at 11:59 Eastern Time on June 26, 2019. Vote at directvote.net/IASLC.
IASLC CEO Dave Mesko sits down with IASLC President-Elect candidate, Dr. Pasi Janne, a translational thoracic medical oncologist at the Dana Farber Cancer Institute and Professor of Medicine at Harvard Medical School. He is also the Director of the Lowe Center for Thoracic Oncology and the Director of the Belfer Center for Applied Cancer Science. Voting is available to active IASLC members and ends at 11:59 Eastern Time on June 26, 2019. Vote at directvote.net/IASLC.
Dr. Jack West is joined by Dr. David Gandara to discuss blood based testing for molecular interrogation, blood based assays for tumor mutational burden, and how the landscape of lung cancer and the IASLC have evolved. Dr. Gandara is Professor of Medicine and Senior Adviser to the Director of Medical Oncology at University of California Davis in Davis, CA and past president of the IASLC.
Dr. Jack West is joined by Dr. Joan Schiller to discuss new developments in the field of lung cancer, the results of the trial ECOG 1594, mentorship in oncology, and women's support and representation in the practice of lung cancer. Dr. Schiller is a medical oncologist with a focus on thoracic oncology, faculty of the University of Virginia and previous chair of the lung cancer committee for the Eastern Cooperative Oncology Group.
Dr. Jack West is joined by IASLC president Dr. Giorgio Scagliotti for discussions on strategic goals of the IASLC and the evolution of staging efforts, the evolution in treating non-squamous non-small cell lung cancer, the status of screening efforts in Europe, and how patients are playing an active role in the study of lung cancer.
Dr. Jack West is joined by Dr. Christine Hann and Dr. Stephen Liu for a discussion on the advancement of therapies in small cell lung cancer. Lung Cancer Considered is the podcast of the International Association for the Study of Lung Cancer (IASLC).